Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Testing efficacy or toxicity of a compound or composition (e.g., drug, vaccine, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424900100 - IN VIVO DIAGNOSIS OR IN VIVO TESTING

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20090175797Inflammation-Inhibitory Serum Factors and Uses Thereof - Disclosed are methods of purifying compounds that reduce or prevent an inflammatory response in a mammal, use of such compounds in treating a mammal having or being at risk of developing inflammation, as well as serum containing such purified compounds. Also disclosed are animal models that are more representative of humans in the study of inflammatory responses or as screening tools for discovering or developing new therapeutics or lead candidate compounds for inhibition of an inflammatory response.07-09-2009
20100034746ANIMAL MODEL, SYSTEM, AND METHOD FOR SCREENING COMPOUNDS FOR ANTITHROMBOTIC AND/OR THROMBOLYTIC ACTIVITY - The present invention relates to a method for evaluating a test compound for antithrombotic activity, thrombolytic activity, or a combination thereof. This method can include providing or employing a donor test animal and a recipient test animal. The donor and recipient test animals can have been pretreated with test compound. The donor test animal can be configured to provide oxygenated blood to the recipient test animal through a thrombus inducing system. This method also includes initiating transport of blood from the donor test animal to the recipient test animal through the thrombus inducing system. The method can include interrupting respiration of the recipient test animal and determining the length of time that the recipient test animal survives. In this method, a survival time longer than a predetermined threshold time indicates that the test compound has antithrombotic activity, thrombolytic activity, or a combination thereof.02-11-2010
20110182819Methods and Compounds for Promoting Vessel Regression - The present invention relates, at least in part, to methods and compositions for treating and diagnosing disorders associated with neovascularization, and methods for identifying targets and compositions used in treating and diagnosing such disorders.07-28-2011
20090324502Nasal Formulations of Insulin - The present invention provides a method for achieving a therapeutically effective plasma levels of insulin by administering at least two doses of pharmaceutical formulation of insulin sequentially into the same nostril. The administration of the second dose in the same nostril gives substantially higher plasma levels of insulin when compared with sequential administration in two different nostrils. Without being limited to any specific physiological mechanism, it is believed that the first dose of insulin acts as a loading dose. This loading dose is required to achieve the subsequent plasma levels of insulin that are observed with subsequent doses. The Cmax of plasma insulin achieved by the methods and formulations of the present invention is at least about 70 microU/ml when plasma insulin is measured from about 0 to about 45 minutes after administration of a second dose. The AUC achieved is at least about 1800 microU/(ml*min). When administered sequentially in the same nostril, the Cmax of plasma insulin after a second dose is about five-fold greater than the Cmax of plasma insulin observed after the first dose; note, plasma insulin is measured from about 0 to about 45 minutes after administration of a second dose.12-31-2009
20080260645METHOD AND USE OF COLD-PRESSED BOTANIC SEED OILS FOR LOWERING BLOOD PRESSURE AND LDL CHOLESTEROL - A method of lowering diastolic blood pressure and LDL cholesterol in a human subject. The method consists of the steps of: (a) administering to the human subject a mixture of cold-pressed botanic seed oils; (b) administering to the human subject the mixture of cold-pressed botanic seed oils and a mixture of botanic seed flours; and (c) lowering the human subject's diastolic blood pressure and LDL cholesterol.10-23-2008
20080260643USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS - A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.10-23-2008
20080260644CHLORIDE TRANSPORT UPREGULATION FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY - Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.10-23-2008
20090252685HIGH PENETRATION PRODRUG COMPOSITIONS OF PROSTAGLANDINS AND RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of prostaglandins or prostaglandin analogs which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent prostaglandins or prostaglandin analogs after crossing the biological barrier and thus can render treatments for the conditions that the parent prostaglandins or prostaglandin analogs can. Additionally, the HPPs are capable of reaching areas that parent prostaglandins or prostaglandin analogs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.10-08-2009
20090123379NOVEL SCREENS TO IDENTIFY AGENTS THAT MODULATE RETINAL BLOOD VESSEL FUNCTION AND PERICYTE FUNCTION AND DIAGNOSTIC AND THERAPEUTIC APPLICATION THEREFOR - The present invention provides methods for determining or identifying compounds that modulate the function of an isolated retinal pericyte or blood vessel, wherein a change in the contractile state of said pericyte or blood vessel is determined in the presence of a test compound, said change indicating that the test compound modulates the function of pericytes and/or blood vessels.05-14-2009
20090123376THERAPEUTIC AGENTS WITH DECREASED TOXICITY - The present invention relates to therapeutic agents with reduced toxicity comprising a serum albumin binding peptide (SABP), a targeting agent and a cytotoxic agent. The present invention also relates to methods for reducing the toxicity of therapeutic agents and methods of treatment using the therapeutic agents with reduced toxicity.05-14-2009
20110195026PROTEIN - The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.08-11-2011
20090191127OMENTUM AND USE THEREOF - In some embodiments, mammalian omentum and methods of using the same for treating symptoms and/or conditions related to dementia are provided. In addition, a composition comprising the omentum tissue and/or the extract thereof is described in some embodiments. In some other embodiments, methods of formulating and administering the composition are also provided. In addition, a cultured cell system to culture cells and/or tissues of the omentum is described. Some aspects of embodiments provide methods of identifying one or more biological agent from the omentum tissue. In another aspect of the embodiments, methods of testing the effect of stimulation omentum in treating dementia conditions are described.07-30-2009
20100074846Campylobacter Vaccines and Methods of use - Porcine models for studying bacterial gastritis and gastric and duodenal ulcer disease caused by 03-25-2010
20120244077METHODS AND COMPOSITIONS FOR MAINTENANCE OF A FUNCTIONAL WOUND - The present invention relates to methods and compositions for the modulation of wound healing and/or the production of extracellular membrane components by modulating the activity and/or amount of secreted protein acidic and rich in cysteine (SPARC) protein. The invention further provides methods for identifying compounds useful in the above-mentioned methods and compositions.09-27-2012
20130078187Method for Selecting Bacteria with Anti-Oxidant Action - The present invention relates to a method using 03-28-2013
20120183477Therapeutic Antibody Target Validation and Screening In Vivo - An in vivo method of validating a candidate therapeutic target molecule is provided. An in vivo method of selecting a therapeutic antibody to a specific target molecule is also provided.07-19-2012
20100034744Method For Screening Anti-HIV Drugs and A Diagnostic Method of AIDS - The present invention elucidated the interaction between host-side factors and HIV particles, and provided a method for screening anti-HIV-1 drug targeting a new host-side factor. Furthermore, the present invention provided a new diagnostic method of AIDS based on the interaction.02-11-2010
20100119454Use of the conserved Drosophila NPFR1 system for uncovering interacting genes and pathways important in nociception and stress response - The present disclosure provides methods of identifying compositions capable of inhibiting responses to stressors in an organism, as well as recombinant cells and organisms useful in identifying compositions capable of inhibiting responses to stressors in an organism.05-13-2010
20130034500Cationic Steroid Antimicrobial Compositions and Methods of Use - The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).02-07-2013
20130034499SGII AS A PROGNOSTIC MARKER IN CONDITIONS WHICH REQUIRE CRITICAL CARE - The present invention relates to methods for determining the prognosis of a condition which requires critical care, said methods comprising determining the level of SgII, or fragments thereof in a subject. The methods of the invention can also be used to determine whether an individual is suffering from a condition which requires critical care and determining the severity of a condition which requires critical care.02-07-2013
20120207682METHODS OF TREATING MACULAR EDEMA USING ANTIEDEMA THERAPEUTICS - The invention provides methods of treating macular edema in a patient that include determining whether the patient has been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time. If the patient has been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time, the method of treatment includes administering a therapeutically effective amount of an AED to the patient. If the patient has not been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time, the method of treatment optionally includes treating the patient with a therapy other than an AED. The invention further provides methods of treating macular edema in a patient using methods of and devices for administering an AED.08-16-2012
20130039856Products and Methods - The present invention concerns medicaments for slowing ageing. The medicaments can include an inhibitor of microbial folate biosynthesis as well as agents capable of reducing folate uptake by an animal. Examples of such medicaments include inhibitors that reduce the activity of an enzyme in the folate biosynthesis pathway, such as sulfonamides including sulfamethoxazole. The invention also concerns a food supplement, additive, functional food, or nutraceutial comprising the inhibitor or agent or composition as discussed above, as well as methods for screening for an agent for use as a medicament for slowing ageing comprising determining whether a test agent inhibits microbial folate biosynthesis, or whether the test agent reduces folate uptake by a non-human animal.02-14-2013
20130039857METHODS OF SUPPRESSING CANCER, INCREASING WEIGHT LOSS AND/OR INCREASING INSULIN SENSITIVITY - The present invention provides methods for determining if an agent (i) treats or prevents cancer, (ii) treats or prevents obesity, and/or (iii) increases insulin sensitivity, comprising contacting Fyn and/or LKB1 with the agent and determining if the agent inhibits Fyn kinase activity or inhibits the interaction between Fyn and LKB1, wherein inhibition of Fyn kinase activity or inhibition of the interaction between Fyn and LKB1 by the agent indicates that the agent (i) treats or prevents cancer, (ii) treats or prevents obesity, and/or (iii) increases insulin sensitivity. The present invention also provides methods for treating cancer, treating obesity, or increasing insulin sensitivity in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits Fyn kinase or that inhibits the interaction between Fyn and LKB1.02-14-2013
20100098638RIP140 Regulation of Diabetes - Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat.04-22-2010
20100111874METHOD OF CANCER DETECTION AND TREATMENT - The present invention provides methods for detecting and treating cancer. In some embodiments, levels of ISG15 are determined, and topoisomerase I and II inhibitors as well as other DNA-damaging agents plus agents that increase the expression of ISG15 are selected and administered.05-06-2010
20100111873TREATING CANCER WITH VIRAL NUCLEIC ACID - This document provides methods and materials related to the use of nucleic acid coding for viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, methods for making engineered viral nucleic acid, methods for identifying infectious nucleic acid for treating cancer, methods and materials for controlling virus-mediated cell lysis, and methods and materials for assessing the control of virus-mediated cell lysis are provided.05-06-2010
20130209366Glutathione-Lanthionine Compounds and Methods Related Thereto - The present invention concerns glutathione-lanthionine compounds, the process of preparing such compounds, and their use. The invention also concerns methods of using the compounds and derivatives and combinations of these compounds in the treatment and/or prevention diseases, including diseases affecting the central nervous system.08-15-2013
20090155180Methods and targets for identifying compounds for regulating rhinovirus infection - The present invention provides methods for identifying genes, expression regulators, receptors, protein product receptors, and proteins that may regulate rhinovirus infections. The genes identified may be used as markers for disease onset and progression and to measure efficacy of a therapeutic. The present invention also provides methods to screen agents that are capable of regulating rhinovirus infection. The present invention also provides methods of identifying therapeutic compounds that may treat various disorders by regulating the expression and activity of genes, expression regulators, receptors, protein product receptors, and proteins identified.06-18-2009
20100040552METHODS TO EVALUATE GLUCOCORTICOID RECEPTOR AGONISTS AND ANTAGONISTS FOR EFFECTS ON NEURON-LIKE CELLS - The present invention provides methods for identifying a modulator of glucocorticoid receptor activity. In one embodiment, the methods include the steps of (a) contacting neuron-like cells, in vitro, with a chemical agent; (b) measuring the expression of a member, or group of members, of a group of genes (as defined herein) in the neuron-like cells contacted with the chemical agent; and (c) determining whether the chemical agent significantly alters the expression of the member, or group of members, of the group of genes, thereby determining whether the chemical agent is likely to be a modulator of glucocorticoid receptor activity. In another embodiment, an in vivo method for identifying a modulator of glucocorticoid receptor activity is provided.02-18-2010
20100040551Animal Model of Central Neuropathic Pain and Methods of Making and Using the Same - The present disclosure describes an animal model of central neuropathic pain relevant to spinal cord injury, as well as methods of using the model to screen for therapeutic agents and to test existing therapies.02-18-2010
20100028263Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus - compositions, especially those based on 02-04-2010
20100143256ELECTROENCEPHALOGRAPHY BASED SYSTEMS AND METHODS FOR SELECTING THERAPIES AND PREDICTING OUTCOMES - A method and system for utilizing neurophysiologic information obtained by techniques such as quantitative electroencephalography (QEEG), electrode recordings, MRI in appropriately matching patients with therapeutic entities is disclosed. The present invention enables utilization of neurophysiologic information, notwithstanding its weak correlation with extant diagnostic schemes for mental disorders, for safer and expeditious treatment for mental disorders, discovering new applications for therapeutic entities, improved testing of candidate therapeutic entities, inferring the presence or absence of a desirable response to a treatment, and deducing the mode of action of one or more therapeutic entities. In particular, methods for effectively comparing neurophysiologic information relative to a reference set are disclosed along with database-based tools for deducing therapeutic entity actions on particular patients such that these tools are readily accessible to remote users.06-10-2010
20130034501DIARYLHYDANTOIN COMPOUNDS - The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone lefiactory prostate cancer.02-07-2013
20100329988Method for Identifying Within a Mammal a DNA Encoding A Physiologically Active Polypeptide - The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance.12-30-2010
20120164075ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES - The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases, infectious diseases, fertility disorders, osteoporosis, osteoarthritis, and/or cardiovascular diseases. Specifically, the present invention relates to compositions comprising endoxifen for use in the treatment of such disorders or predisposition to such disorders, for use in manufacture of medicaments for treating such disorders, and methods comprising use of such compositions in such treatments.06-28-2012
20120164073Stable nanoparticles, nanoparticle-based imaging systems, nanoparticle-based assays, and in vivo assays for screening biocompatibility and toxicity of nanoparticles - Nanoparticles, such as noble metal nanoparticles, having improved stability against aggregation in aqueous solution are provided. In addition to having improved stability against aggregation, the nanoparticles are highly photostable. Also provided are aqueous solutions containing the stabilized nanoparticles, methods of making the stabilized nanoparticles, imaging methods and organisms employing the nanoparticles, and in vivo assays for screening and characterizing the toxicity and biocompatibility of the nanoparticles.06-28-2012
20130028843KALLIKREIN 7 MODULATORS - The present invention relates to the crystal structure of the serine protease kallikrein 7 and to the use of this crystal structure in drug discovery. The present invention also relates to compounds binding specifically to this active site of kallikrein 7.01-31-2013
20130028842METHOD OF TREATING BINGE EATING DISORDER - The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the pro drug to treat certain disorders, and optionally one or more other active agents are provided by the invention.01-31-2013
20090324501Vaccine Carrier - The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.12-31-2009
20090304596Methods for Predicting Psychotropic Drugs Which Elicit Weight Gain - The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We found that orexigenic AAPDs potently and selectively activate hypothalamic AMP kinase (AMPK), an action abolished in mice with deletion of histamine H1 receptors. These findings afford a means of developing better therapeutic agents and provide insight into the hypothalamic regulation of food intake.12-10-2009
20090304595ANIMAL MODEL AND A METHOD FOR PRODUCING AN ANIMAL MODEL - The present invention discloses a non-human animal model for a hereditary autosomal dominant disease. The non-human animal model expresses at least one phenotype associated with the disease and is obtained by a genetic determinant. The invention also relates to sperm cells and embryos comprising the genetic determinant for an autosomal dominant disease. Furthermore, methods for producing the non-human animal model, sperm cell, and embryos are disclosed.12-10-2009
20090041667Treatment of Depressive Disorders - The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders.02-12-2009
20130071330METHODS OF IDENTIFYING AGENTS EFFECTIVE TO TREAT COGNITIVE DECLINE AND DISEASES ASSOCIATED THEREWITH - Embodiments described herein are directed to methods of identifying agents effective to treat cognitive decline and diseases associated therewith. Embodiments described herein are also directed to kits for performing methods described herein. Embodiments described are also directed to methods of diagnosis and uses of the same.03-21-2013
20130071331NON-DIFFUSIVE BOTULINUM TOXIN CAUSING LOCAL MUSCLE PARALYSIS, AND PURIFICATION METHOD THEREOF - A method for purifying a non-spreading botulinum toxin that causes local muscle paralysis and a non-spreading botulinum toxin obtained thereby includes the steps of: subjecting a purified botulinum toxin type A product to ion-exchange chromatography using a controlled pH of buffer, concentration of sodium chloride (NaCl), thereby separating the botulinum toxin type A product into subfractions; and collecting a subfraction having an A260/A280 value in a specific range from the separated subfractions.03-21-2013
20130136694METHOD FOR IDENTIFYING CANCER DRUG CANDIDATES IN DROSOPHILA - A process for preparing information that identifies a compound as capable of perturbing the epithelium in a 05-30-2013
20090092553MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS - MCT1 and MCT4 are expressed at higher levels in many cancer cells than comparable normal cells of the same tissue. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the MCT1 and/or MCT4, as well as inhibitors and substrates of MCT1 and/or MCT4, methods of isolating the same, and methods of using the same for treatment or diagnosis of cancer.04-09-2009
20130058868METHOD FOR THE TREATMENT OF T CELL MEDIATED CONDITIONS BY DEPLETION OF ICOS-POSITIVE CELLS IN VIVO - The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.03-07-2013
20090155179KINETIC BIOMARKER FOR QUANTIFICATION OF LYMPHOPROLIFERATION, CLONAL EXPANSION, RECRUITMENT AND TRAFFICKING IN LYMPHOID TISSUES AND OF THE IN VIVO ACTIONS OF ANTIGENS AND MODULATING THEREON - The methods of the present invention allow for the measurement of proliferation, clonal expansion trafficking and/or recruitment of lymphocytes into lymphoid tissue in an in vivo setting. Proliferation, clonal expansion, recruitment and/or trafficking of lymphocytes are measured by using stable isotopes to label newly synthesized DNA, isolating the newly-labeled DNA, and quantifying enrichment of the isolated DNA with mass spectrometry or other appropriate techniques. Such methods are useful in screening candidate drugs for stimulatory or inhibitory effects on proliferation, clonal expansion, recruitment and/or trafficking of lymphocytes. The methods also allow for the discovery of therapeutic agents in disorders of immune regulation such as HIV infection and for optimizing vaccine efficacy.06-18-2009
20110014128CYTOKINE RECEPTOR MODULATORS, METHOD OF IDENTIFYING SAME, AND METHOD OF MODULATING CYTOKINE RECEPTORS ACTIVITY WITH SAME - The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and/or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed. Also disclosed are methods for treating patients with a disease or condition associated with abnormal cytokine receptor mediated function or activity such as inflammatory, autoimmune and vascular diseases.01-20-2011
20110014127METHODS FOR MEASURING A PATIENT RESPONSE UPON ADMINISTRATION OF A DRUG AND COMPOSITIONS THEREOF - Described herein are methods for effectively and accurately measuring a patient response upon administration of one or more drugs to the patient. The methods are more sensitive than current methodologies. Also described herein are compositions comprising an analgesic and a sufficient amount of an antihistamine to enhance the analgesic properties of the analgesic. With respect to these compositions, the methods described herein are useful for evaluating qualities of pain, definite improvement, and one or more bodily functions of a subject afflicted with pain. The compositions described herein are useful in improving the quality of pain in a subject or a bodily function of a subject afflicted with pain or definite improvement of a subject afflicted with pain.01-20-2011
20090269281Calcium/Calmodulin-Dependent Protein Kinase Kinase as a Control Point for Cardiac Hypertrophy - The present invention includes compositions and methods for treating a patient with cardiac hypertrophy by providing the patient with an effective amount of a Calmodulin kinase kinase inhibitor that is sufficient to treat cardiac hypertrophy.10-29-2009
20090269280METHOD FOR ACTIVATION OF TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY A, MEMBER 1 USING ACETALDEHYDE - The present invention relates to a method for activation of TRPA1 (transient receptor potential cation channel, subfamily A, member 1) using acetaldehyde, more precisely a method for selecting a candidate for TRPA1 activation blocker from neurons activated by acetaldehyde. Acetaldehyde of the present invention works on TRPA1 specifically so that it facilitates the isolation of sensory neurons expressing TRPA1. Therefore, acetaldehyde of the invention can be effectively used for the studies on TRPA1 mechanisms and the development of a TRPA1 based anodyne.10-29-2009
20130064775USE OF RILUZOLE FOR TREATING OR PREVENTING THE ADVERSE EFFECTS OF ANTINEOPLASTIC AGENTS - This invention relates to riluzole for use in the treatment or prevention of adverse effects associated with the administration of anticancer agents having neurotoxic effects, such as, for example, platinum salts, taxanes and periwinkle alkaloids.03-14-2013
20130064774METHODS AND COMPOSITIONS FOR MAINTENANCE OF A FUNCTIONAL WOUND - The present invention relates to methods and compositions for the modulation of wound healing and/or the production of extracellular membrane components by modulating the activity and/or amount of secreted protein acidic and rich in cysteine (SPARC) protein. The invention further provides methods for identifying compounds useful in the above-mentioned methods and compositions.03-14-2013
20130064773DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF - The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.03-14-2013
20090252684Determination of tissue-specific profile of amino acid requirements form the relationship between the amounts of tRNAs for individual amino acids and the protein-bound amino acid profile of the tissue - Systems and methods by which optimal profiles of amino acids for specific tissues can be determined. The results of these systems and methods can then be sued to generate medical nutrition products targeting specific tissues either to enhance growth of specific tissues by providing complementary amino acids in a nutritional supplement or pharmaceutical composition form. They can also be used to generate similar medical nutrition products to inhibit growth of particular tissues, such as those that are cancerous10-08-2009
20090238763HIGH PENETRATION COMPOSITIONS AND USES THEREOF - The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.09-24-2009
20090232740Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease - A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with said substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of said electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy.09-17-2009
20090232739Method of in Vivo Screening for cardiac Toxic Agents Using Teleost - This invention relates to a method of screening agents for cardiotoxicity based on the observations of the alteration of heart rate and heart rhythm, using teleost embryos and larvae. This invention also relates to a method for identification of gene(s) related to cardiac functions in teleost.09-17-2009
20090047217Polynucleotides Encoding Members of the Human B Lymphocyte Activation Antigen B7 Family and Polypeptides Encoded Thereby - The present invention provides novel isolated BLAA polynucleotides and the membrane-associated or secreted polypeptides encoded by the BLAA polynucleotides. Also provided are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant or fragment of the BLAA polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BLAA polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.02-19-2009
20120114561METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS - Methods for treating neurodegenerative disorders, including Parkinson's disease, are provided. The methods comprise administrating a therapeutically effective amount of oxytocin or oxytocin analogs to alleviate one or more symptoms of Parkinson's disease. Methods for determining the effectiveness of oxytocin therapy by itself or in addition to one or more adjunctive therapies in alleviating one or more symptoms of Parkinson's disease are also discussed.05-10-2012
20090010850Formulations and methods for treating dry eye - The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.01-08-2009
20100086485INFLUENZA VACCINE - The present invention relates to a live-attenuated bacterial cell comprising a heterologous nucleotide sequence encoding at least one influenza virus antigen in operative linkage to an expression system.04-08-2010
20100086486GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.04-08-2010
20100086487Papio cynocephalus Toll-Like Receptor 3 - Isolated polynucleotides encoding 04-08-2010
20120237449METHODS FOR TREATING NEURAL CELL SWELLING - A composition comprising a novel Ca09-20-2012
20120237448SPHINGOSINE KINASE TYPE 1 INHIBITORS, AND PROCESSES FOR USING SAME - Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).09-20-2012
20090123378Uses and compositions for treatment of ankylosing spondylitis - The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject.05-14-2009
20120121513PLATFORM TECHNOLOGIES FOR SPONTANEOUSLY OCCURRING DISEASES - The invention provides platform technologies for spontaneously occurring diseases that can be used for translational medicine. Non-human companion animals, such as dogs, spontaneously develop diseases that mirror human diseases. Using companion animals that develop spontaneously occurring diseases can benefit the time and cost for translational medicine by allowing for testing of one or more parameters that would otherwise not be permitted under FDA regulations. Furthermore, that could cure or treat their spontaneously occurring diseases.05-17-2012
20110280807Methods and Models for Stress-Induced Analgesia - The invention disclosed relates to methods and models for enhancing stress-induced analgesia through non-opioid mechanisms.11-17-2011
20110044909ANIMAL MODEL FOR DIABETES - The present invention provides a method of producing diabetic mice and their use in drug development.02-24-2011
20110280809PDIA4, TARGET OF CYTOPILOYNE DERIVATIVES, FOR TUMOR DIAGNOSIS AND TREATMENT - Methods of diagnosing cancer that are based in part on the findings that Pdia4 promotes cell growth, cell proliferation, and cell cycle are disclosed herein. Methods of using microvessel density as a surrogate marker and reducing tumor microvessel density in a subject are also enclosed herein.11-17-2011
20110280808Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins - The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.11-17-2011
20090196825CD38 AND OBESITY - This document provides methods and materials relating to obesity. For example, methods and materials related to treating obesity and identifying agents having the ability to treat obesity are provided.08-06-2009
20120189549DEVICE FOR AUTOMATING BEHAVIORAL EXPERIMENTS ON ANIMALS - The present invention enables testing the effect of one or more test agent(s) on one or more animal(s) of a group of animals, preferably insects, to identify agents that affect behavioral properties of the animals. The invention is comprised of the steps of providing animals suitable for testing, bringing those animals into contact with the test agent(s), moving the animals from a growth container to isolate them, prepare and separate the animals for singulation, relocated the animals to a behavior arena, subject the animals to behavioral tracking to assess their behavioral state, and removing the animals from the behavioral tracking to facilitate iterative analysis of further groups. The invention enables a method for preparing a therapeutic compound for the treatment of an animal disease.07-26-2012
20100209348METHODS FOR DETERMINING LIPOSOME BIOEQUIVALENCE - This invention provides methods for determining liposome bioequivalence between a generic drug product and a reference brand-name product. Specific methods for determining bioequivalence between doxorubicin hydrochloric acid (HCl) liposome injection product (Doxil®) and a generic pegylated liposome doxorubicin product are disclosed herein.08-19-2010
20100068147DENGUE DIAGNOSIS AND TREATMENT - We describe a method of providing an indication useful in the diagnosis or prognosis of dengue, the method comprising detecting a change in the expression pattern or level of: (a) a ubiquitin-proteasome pathway protein; (b) a interferon-related protein; or (c) an NF-κB-mediated cytokine/chemokine response protein. We also describe a method of identifying a molecule suitable for the treatment or prevention of dengue, the method comprising determining if a candidate molecule is an agonist or antagonist of any one or more of these proteins.03-18-2010
20090297450Tumor homing molecules, conjugates derived therefrom, and methods of using same - The present invention provides tumor homing molecules, which selectively home to a tumor. The invention also provides methods of using a tumor homing molecule to target an agent such as a drug to a selected tumor or to identify the target molecule expressed by the tumor. The invention also provides methods of targeting a tumor containing angiogenic vasculature by contacting the tumor with a molecule that specifically binds an α12-03-2009
20100266503Breast Cancer Methods, Medicaments and Agents - A method of combating breast cancer in a mammalian individual, the method comprising administering to the individual an agent which reduces the function of the gamma secretase (GS) complex.10-21-2010
20100266504CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF - Provided are a condensed pyridine derivative having a serotonin 5-HT10-21-2010
20110091388USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS - A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.04-21-2011
20110008258METHODS RELATING TO BREATHING DISORDERS - Methods for treating breathing disorders by inhibition of the induced PGE01-13-2011
20110020234RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a 01-27-2011
20100183519Topical Poloxamer Formulations for Enhancing Microvascular Flow: Compositions and Uses Thereof - This invention relates to therapeutic compositions comprising a surface active copolymer, such as poloxamer-188, in an amount effective to enhance microvascular blood flow and/or inflammation in injured skin or other tissue, and methods of using the therapeutic compositions of the invention to inhibit decreased blood flow associated with an injury, disease, or disorder.07-22-2010
20110286929MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - The invention provides compositions and methods for therapeutic and diagnostic applications.11-24-2011
20090226375MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF - The present invention relates to the identification of microRNAs that regulate smooth muscle cell proliferation and differentiation, including the miR-143/miR-145 cluster. Methods of treating restenosis and neointima formation by increasing expression of miR-143 and/or miR-145 are disclosed. The present invention also relates to the identification of two microRNAs, miR-486 and miR-422a, that regulate cell survival in the heart. Methods of treating or preventing cardiac hypertrophy, heart failure, or myocardial infarction by increasing expression of miR-486 and/or miR-422a in heart tissue are also disclosed.09-10-2009
20120009125APOE4 AND APOJ BIOMARKER-BASED PREVENTION AND TREATMENT OF DEMENTIA - Methods, kits, screens, assays, treatments and treatment regimes for treating a patient at risk for or suffering from dementia, and particularly Alzheimer's dementia which are based upon identification of enhanced risk by genotyping APOE and APOJ. In particular, described herein are methods for the prophylactic treatment of dementia based upon results of said genotyping. The systems and methods herein described may be used both to detect and to target the primary genetically mediated pathways associated with amyloid burden. For example, a system for deciding treatment based on previously identified genetic polymorphisms (e.g., APOE4, polymorphism in APOJ) that affect amyloid clearance is described herein; such patients may respond to treatments that modulate glial based GLT-1 (e.g., Tianeptine) and/or enhance HSP expression/activity (e.g., GGA).01-12-2012
20110286930METHODS OF IDENTIFYING MODULATORS OF THE PP2A B56 BETA REGULATORY SUBUNIT - The present invention is based at least in part on the discovery that the PP2A B56 regulatory subunit plays a role in regulating insulin signaling by directly regulating phosphorylation of AKT-I. Accordingly, the present invention features methods of identifying modulators of the PP2A B56 regulatory subunit in assays featuring organisms and/or cells. Further featured are therapeutic methods for the use of PP2A B56 regulatory subunit modulators to enhance longevity, to prevent or treat cancer, to prevent or reduce obesity and to prevent or treat type II diabetes.11-24-2011
20110286931CARDIAC ARRHYTHMIA TREATMENT METHODS AND BIOLOGICAL PACEMAKER - Disclosed are methods of preventing or treating cardiac arrhythmia. In one embodiment, the methods include administering to an amount of at least one polynucleotide that modulates an electrical property of the heart. The methods have a wide variety of important uses including treating cardiac arrhythmia. Also disclosed are methods and systems for modulating electrical behavior of cardiac cells. Preferred methods include administering a polynucleotide or cell-based composition that can modulate cardiac contraction to desired levels, e.g., the administered composition functions as a biological pacemaker.11-24-2011
20110286928Methods and compositions for inhibition of BCL6 repression - Provided are peptides or mimetics that block corepressor binding to a BCL6 lateral groove. Also provided are methods or blocking corepressor binding to the BCL6 lateral groove. Additionally, methods of inhibiting BCL6 repression in a mammalian cell, and methods of treating a mammal with cancer are provided.11-24-2011
20100239499Methods and compositions for genetic and retinal disease - An inventive method for treatment or prevention of vascular diseases of the retina is provided. A Norrin compound is optionally administered to a subject either directly and/or as expressed by a cell. The presence of the compound is either protective of or therapeutic for a pathological condition of the retina. Preferred pathological conditions are those linked to the absence of or mutation of norrin protein and are preferably Norrie disease, FEVR, or macular degeneration.09-23-2010
20110293526COMPOSITIONS AND METHODS TO MODULATE HAIR GROWTH - The invention provides compositions and methods to modulate hair growth in a tissue comprising administering to the tissue an effective amount of an agent that inhibits or augments Bone Morphogenic Protein (BMP) signaling in the tissue, thereby facilitating or inhibiting hair growth.12-01-2011
20110293524METHODS AND COMPOSITIONS FOR THE REGULATION OF LECTIN COMPLEMENT PATHWAY (LCP)-ASSOCIATED COMPLEMENT ACTIVATION IN HYPERGLYCEMIC MYOCARDIAL DAMAGE - The present invention relates to methods and compositions for regulating lectin complement pathway (LCP)-associated complement activation. In particular, the invention relates to methods and compositions for inhibiting LCP-associated complement activation in order to inhibit hyperglycemic myocardial damage. The invention also relates to the treatment of cardiomyopathy and/or hypertrophy, such as cardiac hypertrophy. The invention also relates to methods and compositions for inhibiting the loss of cardiac progenitor cells by inhibiting LCP-associated complement activation. The methods include both in vitro and in vivo methods. The methods can be accomplished by contacting a mammalian cell having a surface exposed mannose binding lectin (MBL) ligand, such as a cardiac cell, with an effective amount of a MBL inhibitor to inhibit LCP-associated complement activation.12-01-2011
20110293525TUMOR STEM CELLS - Tumor stem cells can be obtained by culturing a tumor cell population, and exposing the cultured tumor cell population to free radicals. In certain embodiments, the free radical agent can be a nitric oxide (NO) donor. In one embodiment, the free radical agent can be Diethylenetriamine NONOate (DETA NONOate) or agents that constitutively increase cellular nitric oxide, such as phosphodiesterase inhibitors or L-arginine, or agents that increase NO synthase in the population. The methods can further include inducing stem cells present in the population to expand and/or inducing dedifferentiation of tumor cells into tumor stem cells. Additionally, the present invention provides methods of selecting stem cells from a tumor cell population. Another aspect provides methods of screening for anti-tumor stem cell teherapeutic compounds by providing high nitric oxide (HNO) tumor cells, exposing the HNO cells to at least one compound, assessing one or more indicators of HNO cell health and determining toxicity of the compound to HNO tumor cells.12-01-2011
20100034745Method for Reducing Levels of Disease Associated Proteins - The subject invention concerns the reduction of protein aggregation in the neurons of a mammal through the use of a ketogenic treatment such as a ketogenic diet, a physical training regimen and/or administration of agents to increase fatty acid oxidation. Such ketogenic treatment can be useful in the reduction of certain aggregates including amyloid β peptide, polyglutamine containing huntintin protein, polyglutamine containing androgen receptor, polyglutamine containing atrophin-1, polyglutamine containing ataxins, α-synclein, prion protein, tau and superoxide dismutase 1 (SOD1).02-11-2010
20110217239SYSTEM AND METHOD OF EVALUATING A PROTEIN OF INTEREST ON TUMOR GROWTH INHIBITION WHILE FOLLOWING THE TUMOR IN VIVO OR IN VITRO - Disclosed herein are systems and methods for evaluating a protein of interest on growth inhibition of a tumor while following the tumor in vivo or in vitro through a co-expressed visible marker. The present disclosure provides an expression composition for stably transforming cells, preferably tumor cells. The expression composition includes two vectors respectively include polynucleotides encoding a protein of interest and a visible marker, wherein each polynucleotide is operably linked to a tet-on system such that the protein of interest and the visible marker are co-expressed upon activation of the tet-on system. The present disclosure also provides stably transfected cell lines, which may be used to access real-time biological processes, including tumor cell proliferation.09-08-2011
20090028796PESTICIDAL COMPOSITION COMPRISING INDOLE DERIVATES - The present invention is directed to pesticidal compositions comprising indole derivatives. These indole derivatives are especially active against phytopathogenic fungi. Furthermore, the invention relates to the use of indole derivatives for the production of pesticides and the use of the compositions according to the invention as pesticides. The present invention is also directed to a process for producing a pesticidal composition and to pesticidal compositions prepared by this process. In addition, the invention relates to a process for preventing or combating pests and to a process for protecting plants against pests, especially against phytopathogenic fungi. Further, the invention is directed to plants or seeds as well as objects or materials which have been protected against pests by treatment with a composition according to the invention. Further, the invention is directed to a method for identifying a substance having pesticidal activity. Further, the invention is directed to a method of identifying the mode of action of and/or of providing binding proteins for a pesticidal compound of the present invention. Finally, the invention is directed to a method for diagnosing pest infection of a plant and to the use of a pesticidal compound of the present invention as diagnostic markers.01-29-2009
20100111872System and method for modulating and optimizing immunotherapy - A method for modulating a subject's type of immune response to a cancer treatment. The method comprises the steps of: (a) obtaining a sample from subject; (b) assessing the sample to detect IgG antibodies or IgG isotypes in the sample; (c) if IgG antibodies or IgG isotypes are detected, then identifying and quantifying their expression; (d) comparing the quantified IgG antibodies or IgG isotypes with a control to determine the changes, and characterize the immune response. The changes in expression of IgG antibodies or IgG isotypes are indicative of the type of immune response to the cancer treatment. Steps (a) through (f) are repeated for each of a series of spaced-apart time points. The series of characterized immune responses are assessed to determine the subject's responsiveness to the cancer treatment. The cancer treatments are then modulated to affect desired changes in expression of IgG antibodies or IgG isotypes.05-06-2010
20100158808Altered Activity of Toll-Like Receptors - Materials and Methods for modulating TLR activity are described, as well as methods for reducing body fat and increasing bone density.06-24-2010
20080241068SYSTEM AND METHODS FOR IDENTIFYING INDIVIDUALS AT RISK FOR SYSTEMIC FLUOROPYRIMIDINE TOXICITY - The present disclosure is related to methods and tests for identifying individuals at risk for systemic toxicity to a substance by administering a topical dose of the substance to the individual and observing any topical response to that substance. In particular, the present disclosure provides methods and tests for determining if an individual is at risk for fluoropyrimidine, such as 5-fluorouracil, toxicity or has a dihydropyrimidine dehydrogenase deficiency by exposing the skin of the individual to a dose of a fluoropyrimidine, such as 5-fluoruracil, using a transdermal skin patch. An inflammatory response of the skin indicates the risk of the individual to such toxicity or enzyme deficiency.10-02-2008
20110014126USE OF VITAMIN D RECEPTOR AGONISTS AND PRECURSORS TO TREAT FIBROSIS - This application relates to methods of treating, preventing, and ameliorating fibrosis, such as fibrosis of the liver. In particular, the application relates to methods of using a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors) for the treatment of liver fibrosis. Also disclosed are methods for screening for agents that treat, prevent, and ameliorate fibrosis.01-20-2011
20110262362METHODS FOR TREATING OBESITY - The present invention provides methods to reduce or inhibit weight gain by administering inhibitors of the SirT1 protein to a subject. Methods to identify such inhibitors are also disclosed.10-27-2011
20090142272Pfks as modifiers of the igfr pathway and methods of use - Human PFK genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of PFK are provided.06-04-2009
20090104120DLX1 CANCER MARKERS - This invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, this invention relates to DLX1 cancer markers that are useful as diagnostic markers and clinical targets for prostate cancer.04-23-2009
20110171135PEST-CONTROL COMPOSITIONS AND METHODS HAVING HIGH TARGET AND LOW NON-TARGET ACTIVITY - Embodiments of the invention relate to compositions and methods for selective pest control wherein the compositions include active agents that in combination have a first activity against a selected target pest and a second activity against a selected non-target organism and wherein the first activity is greater than the second. Further embodiments of the invention relate to a method for developing selective pest control compositions and low-resistance pest control compositions.07-14-2011
20110171133RADIOLABELLED MMP SELECTIVE COMPOUNDS - The invention is directed to radiolabelled MMP selective compounds, a processes for the preparation thereof, and uses thereof. The derivatives of the invention have formula (I) wherein Y represents O, CH07-14-2011
20100119453METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE - The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.05-13-2010
20090257954Development of a simple animal model for infection by viruses and other obligate intracellular parasites - The present invention provides methods for studying pathogenesis of mammalian viruses. In particular, the present invention provides a nonhuman animal model system for studying disease mechanisms wherein the nonhuman animal model is infected with an animal virus. In a preferred embodiment the animal model is 10-15-2009
20090263324Animal Model With Induced Arrhythmia - Provided are a model animal physiologically similar to humans, enabling a highly reproducible evaluation of the onset of drug-induced long QT syndrome, a method of generating the same, and an evaluating method using the same. A proarrhythmia model animal of a monkey, prepared by ablating the atrioventricular node; the foregoing monkey is preferably a cynomolgus monkey. A method of generating a proarrhythmia model animal, comprising a step for inserting an electrode catheter to the heart of a monkey, and ablating atrioventricular node with the catheter, and a method of evaluating the QT interval prolongation by a drug, comprising using the foregoing model animal.10-22-2009
20110200531TREATMENT AND DIAGNOSIS OF CENTRAL NERVOUS SYSTEM DISORDERS - The invention relates to the use of tetramethylpyrazine (TMP) for the treatment of patients at risk for the development of, or diagnosed as having, CNS disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), glaucoma, and Huntington's Disease (HD), as well as traumatic brain injury (TBI). The present invention also relates to the use of retinal imaging to diagnose and monitor efficacy of treatments for such CNS disorders.08-18-2011
20100124533Large Animal Model for Human-Like Advanced Atherosclerotic Plaque - An animal model for cardiovascular disease comprising one or more vascular plaque lesions formed at selected sites within a vascular segment of a nonhuman mammal. The vascular plaque lesion is formed by administering a hypercholesterolemic diet to the nonhuman mammal, inflicting an injury to the vascular wall at the selected site after a predetermined exposure to the hypercholesterolemic diet, and applying a hydrogel to the injured vascular wall. Another aspect of the invention provides a method for evaluating a test compound for an effect on atherosclerotic lesion formation comprising administering to a nonhuman mammal a hypercholesterolemic diet, and, after a defined period of time, isolating a segment of a blood vessel using a balloon catheter, inflicting an injury to the vascular wall within the isolated segment, and applying a hydrogel within the vascular segment. The method further comprises forming a vascular plaque lesion on the vascular wall at the site of the injury, delivering the test compound to the nonhuman mammal, and monitoring atherosclerotic lesion size and composition at the injured site after a defined period of exposure to the test compound.05-20-2010
20100124534IMMUNOTHERAPEUTIC METHOD - The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising: 05-20-2010
20090274627Composition for Regeneration of Periodontal Soft Tissue and Method for Producing the Same - It is intended to provide a composition for regeneration of periodontal soft tissue less invasively and a method for producing the composition. The composition for regeneration of periodontal soft tissue is prepared so as to contain a cell selected from an undifferentiated/stem cell or a blast cell having an ability to form gingiva, a matrix material and blood platelet plasma. With the composition, free gingiva as well as attached gingiva can be regenerated less invasively with an effective and good aesthetics.11-05-2009
20090004113Macrophage-Enhanced MRI (MEMRI) - Methods for assessing stage of cancer in a subject are provided, comprising administering a macrophage imaging agent to the subject, making a magnetic resonance image of regions of the subject's body at cancer risk, and using the image to assess macrophage density and displacement associated with any primary cancer or metastatic cancer in the subject, such density and displacement being indicative of neoplasia. The macrophage imaging agent may be an ultrasmall superparamagnetic iron oxide particle and in particular embodiments, the macrophage imaging agent has a blood half-life sufficient to permit microphage trapping throughout the regions at cancer risk. Additional embodiments provide methods for assessing efficacy of an anticancer treatment in a subject, methods for determining frequency of follow-up MEMRI evaluation in a subject, methods for determining metastatic potential of cancer foci in a subject, and methods for determining prognosis of cancer in a subject. Methods for directing site of biopsy in a subject by performing a whole body MEMRI evaluation of the subject to identify macrophage density at a tumor site of interest and assessing the macrophage density to identify the site of biopsy in the subject, macrophage density being an indicator of tumor growth are also provided, in addition to methods for providing individualized cancer treatment to a subject in need thereof using whole body MEMRI evaluation.01-01-2009
20110171134(6S)-5-METHYLTETRAHYDROFOLIC ACID FOR THERAPY OF TISSUE INJURY - The present invention relates generally to the field of methods useful in treating tissue injury. More specifically, the present invention relates to (6S)-5-methyltetrahydrofolic acid compounds, and methods of using the (6S)-5-methyltetrahydrofolic acid compounds, to treat conditions associated with nervous system injury.07-14-2011
20080206143Blockade of Elr+Cxc Chemokines as a Treatment For Inflammatory and Autoimmune Disease - Experimental autoimmune encephalomyelitis (EAE) is a ThI-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). Herein it is demonstrated that CXCR2, a chemokine receptor involved in the recruitment of neutrophils, is expressed in tissues with EAE lesions. Blockade or deficiency of CXCR2 reduces the infiltration of neutrophils to sites of inflammation. Thus provided herein are reagents that antagonize or inhibit ELR+CXC chemokines and methods of use of these reagents in preventing and treating organ-specific autoimmune diseases like multiple sclerosis, and methods or treating various inflammatory conditions and diseases.08-28-2008
20090280062LONGEVITY-PROMOTING EFFECTS OF ACETIC ACID AND REISHI POLYSACCHARIDE - A composition of acetic acid and a composition of acetic acid and RF11-12-2009
20090285758IN VIVO SYSTEM TO MONITOR TISSUE RESPONSES IN BIRDS - Methods of evaluating the tissue response to an agent in birds are provided. Also disclosed are methods of monitoring exposure to agents in birds and methods of determining the efficacy of vaccines.11-19-2009
20090104122DETECTION OF MEMBRANE ANDROGEN RECEPTOR (mAR) AGENTS - Disclosed are methods to detect agents that modulate a membrane androgen receptor (mAR). In one embodiment, the invention provides a method to detect and optionally identify mAR binding ligands. One assay according to the invention detects agents that selectively bind the mAR relative to binding to the classical intracellular androgen receptor (iAR or AR). The invention has a wide spectrum of useful applications including providing a method of screening libraries for chemical entities that preferentially bind the mAR.04-23-2009
20090104121Multi-subunit biological complexes for treatment of plaque-associated diseases - Provided herein are methods and compositions for the in vitro formation of multi subunit biological platforms. The biological platforms may be used to screen chemical or biological compounds, in particular compounds that may disrupt or otherwise affect the formation of the multi subunit complexes, or disrupt already-formed in vitro assembled multi subunit complexes. Also provided herein are methods and compositions for the in vivo formation of multi-subunit biological complexes. The methods and compositions described herein may be used to develop animal models of diseases or disorders.04-23-2009
20100278742METHODS AND COMPOSITIONS FOR DETECTION AND DIAGNOSIS OF INFECTIOUS DISEASES - Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having active disease, and individuals who have been immunologically exposed, such as those infected with a mycobacterium but are without active disease, or those who have been vaccinated with BCG. The methods comprise topical application of antigen compositions for transdermal delivery.11-04-2010
20110171132Methods, Compounds, and Compositions for Treatment and Prophylaxis in the Respiratory Tract - The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.07-14-2011
20110076235GENES, METHODS, AND COMPOSITIONS RELATED TO NEUROGENESIS AND ITS MODULATION - The present disclosure provides methods for investigating neurogenesis, neural cell proliferation and differentiation. Specifically, the present disclosure relates to methods for identifying pharmaceutical agents capable of modulating neurogenesis and neural cell proliferation, methods of screening for genes that modulate neurogenesis and proliferation of neural progenitor cells, and methods of identifying pharmaceutical agents as candidate modulators of neurogenesis and neural proliferation or differentiation. The present disclosure also relates to methods for identifying pharmaceutical agents to characterize and modulate neurogenesis, pharmaceutical agents identified by such methods, methods for treating patients with such pharmaceutical agents, and compositions containing such pharmaceutical agents. Accordingly, the present methods enable elucidation of the mechanisms that control neurogenesis, brain development and function in healthy animals and in disorders of the nervous system. Furthermore, the present methods facilitate the development of compositions to prevent, improve or stabilize impaired neurogenesis in various nervous system disorders, including cognitive disorders.03-31-2011
20090311188IN VIVO METHODS OF IDENTIFYING COMPOUNDS WHICH TARGET SUPPRESSED CANCER CELLS - In vitro and in vivo methods for identifying compounds capable of targeting suppressed cancer cells such as micrometastatic cells. The in vitro method includes the steps of comparing the response to a test compound of cancer cells grown on a suppressing cell support matrix which causes suppression of a malignant phenotype in a growing cancer cell and on a non-suppressing cell support matrix. The in vivo method includes a step of co-injecting labeled cancer cells with a malignant-phenotype suppressing matrix into a test animal to produce suppressed micrometastatic cells therein.12-17-2009
20090311187Methods for predicting patient response to modulation of the Co-stimulatory pathway - The invention described herein relates to diagnostic and therapeutic methods and compositions useful for predicting the likelihood a patient will have favorable response to the administration of a pharmaceutically acceptable amount of an activator of the immune system (e.g, T-cells).12-17-2009
20090311186METHOD FOR CONTROLLING THE THERAPY OF PATIENTS SUFFERING FROM CARDIAC INSUFFICIENCY BY MEANS OF IN VITRO DETERMINATION OF THRESHOLD VALUES OF VASOACTIVE PEPTIDES - Disclosed is a method for controlling the therapeutic treatment of a patient suffering from cardiac insufficiency. In said method, it is determined how the concentration of at least one of the vasoactive peptides adrenomedullin (ADM), endothelin-1 (ET-1), and/or vasopressin (AVP) changes in the patient's blood after beginning the therapy, and the therapeutic measures are considered to be unsatisfactory and are modified in case said concentration does not decrease at all or not enough in relation to a threshold value for the respective vasoactive peptide.12-17-2009
20100061935METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.03-11-2010
20100278740STREPTOCOCCUS PNEUMONIAE PROTEINS AND NUCLEIC ACID MOLECULES - Protein antigens from 11-04-2010
20080213184METHODS FOR MODULATING A DRUG-RELATED EFFECT OR BEHAVIOR - The present invention provides a method of reducing or preventing a drug-related effect or behavior in a subject by inhibiting N-type calcium channels. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate a drug-related effect or behavior. These methods involve assaying test agent binding to N-type calcium channels or channel subunits. Alternatively, test agents can be screened for their ability to alter the level of N-type calcium channels, channel subunit polypeptide or RNA, or the depolarization-induced inward calcium current mediated by these channels. Finally, the invention also provides a diagnostic method that entails measuring one or more of these levels and determining risk for a drug-related effect or behavior based on comparison to the corresponding level for a control population.09-04-2008
20090035222Techniques for Identifying Molecular Structures and Treating Cell Types Lining a Body Lumen Using Fluorescence - Techniques for detecting fluorescence emitted by molecular constituents in a wall of a body lumen include introducing an autonomous solid support into the body lumen. Cells in a lumen wall of the body lumen are illuminated by a light source mounted to the solid support with a wavelength that excites a particular fluorescent signal. A detector mounted to the solid support detects whether illuminated cells emit the particular fluorescent signal. If the particular fluorescent signal is detected from the illuminated cells, then intensity or position in the lumen wall of the detected fluorescent signal, or both, is determined. These techniques allow the information collected by the capsule to support diagnosis and therapy of GI cancer and other intestinal pathologies and syndromes. For example, these techniques allow diagnostic imaging using endogenous and exogenous fluoroprobes, treating diseased sites by targeted release of drug with or without photoactivation, and determining therapeutic efficacy.02-05-2009
20090311185Peptide having antianxiety activity and screening method therefor - The objects of the present invention are to provide a polypeptide having an antianxiety activity; a therapeutic agent containing the polypeptide; a method for treating anxiety using the polypeptide; a method of screening for a compound capable of activating or suppressing a receptor for the polypeptide and involved in the regulation of anxiety, a salt thereof, or a hydrate of them; and a kit for the screening. There is provided an antianxiety agent containing relaxin-3.12-17-2009
20100129291NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM - The present invention discloses nicotinic desensitizers and methods of selecting, testing, and using them. The present invention provides methods for selecting nicotinic desensitizers from one or more compounds by using receptor, cell, and tissue models; and methods for testing one or more nicotinic desensitizers for their therapeutic utility by using animal models. The present invention also provides compounds of formula (I) and (II) as nicotinic desensitizers. Nicotinic desensitizers of the present invention are useful for the treatment of a wide range of conditions, diseases, and disorders.05-27-2010
20090297452METHOD FOR QUANTIFICATION OF NEUROTOXIN - The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of 12-03-2009
20080274058Isotopically-Labeled Benzofuran Compounds as Imaging Agents for Amyloidogenic Proteins - Benzofuran compounds which contain at least one detectable label selected from the group consisting of 11-06-2008
20120294805DNA regulatory element for the expression of transgenes in neurons of a subject and uses thereof - The present invention provides for a method of evaluating whether a compound is effective in activating a calcium-calmodulin dependent kinase IIα promoter in a human neuronal cell which comprises: (a) contacting the human neuronal cell which has been stably transformed by a recombinant nucleic acid molecule comprising a gene of interest operatively linked to a nucleic acid encoding a calcium-calmodulin dependent kinase IIα promoter which has a nucleotide sequence of the promoter in ATCC Accession No. 98582 with the compound, and (b) comparing the expression level of the gene of interest in the neuronal cell in step (a) with the level in the neuronal cell in the absence of the compound, thereby determining whether the compound is effective in activating the calcium-calmodulin dependent kinase IIα promoter.11-22-2012
20100008859METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS - The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.01-14-2010
20080286204MODULATORS OF CFTR - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.11-20-2008
20110206615PROBE REAGENT FOR MEASURING OXIDATIVE STRESS - The present invention relates to fluorescent or luminescent probe reagents for measuring oxidative stress in a cell or an organism. Examples of the probe reagents include: a fluorescent or luminescent protein and a marker protein; a fluorescent or luminescent protein, a marker protein, and a regulatory factor; or a fluorescent or luminescent protein, a marker protein, a cleavage sequence, and a regulatory factor. In the probe reagents, the marker protein makes it possible to detect the oxidative stress caused by reactive oxygen species and comprises a regulatory factor-binding site and a ubiquitin-binding site; and the regulatory factor is a protein making it possible to regulate degradation of the marker protein in response to the reactive oxygen species. The present invention also relates to a method of measuring oxidative stress in a cell or an organism, or a method of screening a substance which suppresses or promotes the oxidative stress in a cell or an organism by using the probe reagent.08-25-2011
20100135910Modulation of Anergy and Methods for Isolating Anergy-Modulating Compounds - The present invention provides methods for identifying compounds capable of modulating anergy by inhibiting the production or activity of anergy associated E3 ubiquitin ligases or by altering the interaction between a ligase and its substrate.06-03-2010
20090123377Method for Testing Substances or Mixtures of Substances,Use of Said Method and Corresponding Test Kits - The invention relates to a method for testing substances and mixtures of substances for toxic characteristics, to the use of said method and to corresponding test kits. The method is essentially based on the determination of a fatty acid binding protein from the liver, L-FABP. The use of said method provides an early indication of carcinogenic and tumour-promoting characteristics of the tested substance or mixture of substances.05-14-2009
20090022667METHODS OF TREATING COGNITIVE DISORDERS BY INHIBITION OF Gpr12 - The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or Gpr12 function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating Gpr12-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation by inhibiting Gpr12 function and methods for treating a defect in performance of a hippocampal-dependent cognitive task by inhibiting Gpr12 function.01-22-2009
20110206614SYSTEMIC INSTIGATION SYSTEMS TO STUDY TUMOR GROWTH OR METASTASIS - The present invention provides tumor instigation systems that can be used to characterize tumor growth and/or metastasis. In some embodiments, the present invention provides a method for studying tumor outgrowth or metastasis including the steps of: (a) providing an animal host; (b) introducing into the animal host one or more cells that instigate the growth of an otherwise indolent tumor; (c) introducing into the animal host a tumor; wherein the presence of the one or more cells or a progeny thereof in the animal host enhances the growth and/or metastasis of the tumor. Among other things, the inventive methods and systems in accordance with the present invention can be used to identify modulators and/or contributors of tumor growth or metastasis, as well as diagnostic and/or therapeutic agents for use in monitoring and/or modulating tumor growth and/or metastasis.08-25-2011
20120093730MOLECULAR DEATH TAGS AND METHODS OF THEIR USE - In one embodiment, a death tag for targeting a cell death marker is provided, the death tag comprising a death marker binding domain; a reporter binding domain (RBD); and a reporter component that is associated with the reporter binding domain. In another embodiment, a method of determining the efficacy of a cancer treatment is provided. The method may comprise administering to a subject an effective dose of a death tag that targets apoptotic, necrotic or dead cells; exposing the subject to an imaging technique; determining that the cancer treatment is effective when the imaging technique detects the presence of the death tag. In another embodiment, an in vivo, ex vivo, or in vitro method of determining the need for a treatment or determining the efficacy of a treatment in cell, tissue, and organ injuries.04-19-2012
20120070379IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.03-22-2012
20120070378LANTHANIDE ION COMPLEXES AND IMAGING METHOD - A Ianthanide complex, method of forming and method of using the lanthanide complex as a near-infrared luminescent material are described. The complex includes at least one lanthanide ion and at least one polydentate ligand derived from a molecule having the general formula of Structure: Structure 2, where: E represents a heteroatom or heteroatom-containing group and R03-22-2012
20090185980IN VIVO DRUG SCREENING SYSTEM - The present invention provides imaging devices. The present invention also provides in vivo drug screening systems. The present invention further provides a method for in vivo drug screening.07-23-2009
20130121919HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF - The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.05-16-2013
20130121920METHODS FOR EVALUATING DERMAL FILLER COMPOSITIONS - The present invention provides methods for evaluating dermal fillers for discoloration potential.05-16-2013
20080317672DETECTION OF ANOMALIES IN MEASUREMENT OF LEVEL OF HYPNOSIS - The invention relates to detection of anomalies related to a measurement of the hypnotic level of a subject. In order to detect when a measure indicative of the hypnotic level of a subject is anomalous either due to a medical reason or due to an interference, the measure is monitored and state information indicative of the activity of the autonomous nervous system of the subject and drug effect information indicative of the hypnotic drug effect in the subject are employed to check whether the measure fulfills a predetermined consistency condition requiring that the measure changes consistently with at least one of the drug effect information and the state information. An anomaly, indicative of an abnormal change in the measure, is detected when the measure fails to fulfill the predetermined consistency condition.12-25-2008
20110223108GLUCAGON-LIKE PEPTIDE-2 AND ITS THERAPEUTIC USE - Glucagon-like peptide 2, a product of glucagon gene expression, and analogs of glucagon-like peptide 2, have been identified as gastrointestinal tissue growth factors. Their effects on the growth of small bowel and pancreatic islets are described. Their formulation as a pharmaceutical, and their therapeutic use in treating disorders of the bowel, are described.09-15-2011
20090081127Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response - The present invention relates to a method of producing a plurality of dendritic cell/tumor cell hybrids which induce an anti-tumor response when applied to a patient. The present invention further relates to a method of producing a dendritic cell/tumor cell hybridoma which induces an anti-tumor response when applied to a patient.03-26-2009
20090098054METHODS AND COMPOSITIONS RELATING TO PROMOTER REGULATION BY MUC1 AND KLF PROTEINS - This invention relates to regulation of cell signaling, cell growth, and more particularly to the regulation of cancer or inflammatory cell growth and/or activation. The invention provides methods of, and compositions useful for, inhibiting interactions between MUC1 and a kruppel-like factor (KLF), method of inhibiting interactions between a KLF protein and the p53 promoter, methods of inhibiting the interaction between MUC1 and the p53 promoter, methods of increasing p53 activity, and methods of increasing histone acetylation. The invention also provides screening methods for identifying compounds that inhibit the aforementioned interactions. Pharmaceutical compositions containing the identified compounds can be useful in treating cancers and inflammatory conditions.04-16-2009
20090081125Angiogenetic Agent Containing Adrenomedulin as the Active Ingredient - It is intended to provide an angiogenic agent which contains, as the active ingredient, at least one substance selected from the group consisting of adrenomedullin, a substance inhibiting the activity of adrenomedullin degrading enzyme, an adrenomedullin receptor activity-modifying protein, a calcitonin receptor-like receptor and an adrenomedullin receptor.03-26-2009
20090081126Novel fully human anti-VAP-1 monoclonal antibodies - Novel fully human anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-1 antibodies are also given. Pharmaceutical compositions comprising said antibodies and therapeutic uses thereof are also disclosed.03-26-2009
20110229413TREATMENT OF AMYLOIDOGENIC DISEASES - The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.09-22-2011
20090098055Methods and Compositions for Diagnosing Disease - The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a disease or disorder or the effectiveness of a treatment for a disease or disorder.04-16-2009
20090098056ALPK1 GENE VARIANTS IN DIAGNOSIS RISK OF GOUT - The present invention relates to a method of identifying a human subject having an elevated risk of gout and/or hyperuricemia by detecting the occurrence of at least one SNP associated with an elevated risk of gout in an ALPK1 gene in a biological sample from the subject, or by determining the expression level of an ALPK1 gene in a biological sample from the subject. Also disclosed is an isolated nucleic acid molecule, its complement or gene variant comprising at least one of the polymorphisms identified herein to be associated with gout and/or hyperuricemia, a kit for performing a diagnostic test to identify a human subject having an elevated risk of gout and/or hyperuricemia, and a method of selecting or identifying a compound useful for treating gout and/or hyperuricemia.04-16-2009
20110229412ANIMAL MODEL OF CENTRAL NEUROPATHIC PAIN AND MEHTODS OF MAKING AND USING THE SAME - The present disclosure describes an animal model of central neuropathic pain relevant to spinal cord injury, as well as methods of using the model to screen for therapeutic agents and to test existing therapies.09-22-2011
20110020233IDENTIFICATION OF PROTECTIVE ANTIGENIC DETERMINANTS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF - The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV.01-27-2011
20090136428High Throughput Genetic Screening Of Lipid And Cholesterol Processing Using Fluorescent Compounds - The present invention utilizes fluorescent lipids, particularly quenched phospholipid or cholesterol analogues, to facilitate screening for phenotypes representing perturbations of lipid and/or cholesterol processing in a vertebrate; screening for genetic mutations that lead to disorders of phospholipid and/or cholesterol metabolism; and screening of compounds designed to treat disorders of phospholipid and/or cholesterol metabolism in the vertebrate.05-28-2009
20090004111Structure of the Hepatitis C Ns5a Protein - The present invention provides a crystallized N-terminal domain of an NS5A protein of hepatitis C virus, methods of producing the same and methods of use thereof. The present invention also relates to structural elements of the N-terminal domain of hepatitis C virus NS5A protein, and methods of inhibiting hepatitis C virus infection, replication and/or pathogenesis, by interacting with the same.01-01-2009
20090220425Method to Quantitatively Measure Effect of Psychotropic Drugs on Sensory Discrimination - A method for evaluating an effect of a psychotropic compound or a treatment on a neuronal activity of an animal including determining a change in the amount of information generated by neurons in response to at least one repeatedly applied stimulus, wherein the change is caused by administering the psychotropic compound or a treatment. Also provided is a method of screening psychotropic compounds for effectiveness on an animal which involves using a change in sensory discrimination in a population of neurons of the animal, wherein the sensory discrimination is obtained in response to one or more stimuli repeatedly applied to the animal and wherein a change in the sensory discrimination occurs due to administering said psychotropic compounds to the animal.09-03-2009
20090226373METHOD OF DETERMINING THE EFFECT OF A SPILL ON A MARINE ENVIRONMENT - A method of determining the effect of a spill on a marine environment, in which physical and chemical sensors are arranged with living organisms (09-10-2009
20090220427Drug Resistance and Methods of Reversing - Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to determine whether an individual (cancer cells in an individual) is sensitive to chemotherapy with plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). Early identification of chemoresistance in patients with cancer is of utmost importance, particularly since it makes it possible to provide the most appropriate therapy.09-03-2009
20090246138METHOD OF IMAGING METABOLIC FUNCTION - A contrast imaging method e.g. of the T2* weighted “BOLD” type is adapted by use together with an oxygen challenge to provide imaging for the assessment of the metabolic responses of tissue over a period of time the method utilizing three components, oxygen, deoxyhaemoglobin, and oxyhaemoglobin together with time, to provide four variable parameters which allows oxygen to be used as a metabolic marker that can be utilized in an imaging evaluation of soft tissue and organs, e.g. in the study of viable tissue and organ function or dysfunction, which allows utility in diagnosis and assessment of conditions such as cancer, dementia, circulatory disorders, and autoimmune disorders.10-01-2009
20090252683Composition Comprising Cross-Species-Sepecific Antibodies and uses Thereof - The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.10-08-2009
20120195834METHOD OF TESTING A DRUG FOR ANTI-CANCER ACTIVITY - A method for separating tumor cells with lymphotropic metastatic potential from those without lymphotropic metastatic potential in a human carcinoma. Cells of the carcinoma are transplanted in each of a plurality of fresh athymic mice. At least one of the athymic mice which does not develop a palpable tumor at the transplant site is treated to suppress the T-cell independent innate anti-tumor activity of natural killer cells therein. Tumor-forming cells at the transplant site of the treated athymic animal are harvested to obtain a cell line of cells with lymphotropic metastatic potential, which is also tested for the expression of T-lymphocyte associated molecules. Such cells are intimately associated with low or diminished angiogenicity and immunogenicity. The traditional scientific criteria for human cancer cells is re-defined, and therapeutic targets for human cancer cells is re-focused.08-02-2012
20100150842Method and Kit for Detecting Resistance in Living Organisms - The present invention concerns the detection of resistance in a living organism, e.g., herbicide resistance in weed crops. Based on non-separated compounds obtained from an organism, e.g., an extract from a plant, a color development is generated. The color or shade developed is dependent on the compounds of the organism. By comparing the color or shade of the extract obtained from an organism with a standard color scale developed with respect to the same organism, it is possible to determine if the organism is resistant to a pesticide, e.g., a herbicide. The invention also concerns a method of providing a standard color scale for material from a living organism that has been exposed to stress, e.g., a pesticide. As assay kit for the determination of whether material from a living organism is resistant to a pesticide is also described. The present invention may be used by farmers or advisors to test if the plants have developed resistance to a herbicide.06-17-2010
20100183518Vaccine Against Group A Beta Hemolytic Streptococcus And Respective Process For Obtaining Thereof - VACCIN AGAINST GROUP A BETA HEMOLYTIC STREPTOCOCCUS AND RESPECTIVE PROCESS FOR OBTAINING THEREOF, which predicts the production of recombinant protein cloned from the gene emm5, which contains a sequence of oligonucleotides corresponding to 52 and/or 87 amino acid residues capable of protection, isolated after the sequential molecular identification of the epitopes from the M protein carboxy-terminal region, differing in 01 amino acid residue, identified by antibodies and T lymphocytes of health human beings and of patients carriers of rheumatic fever, capable of generating a protective response by antibodies depending on the T lymphocytes; prevention of the development of the autoimmune disease by the selected epitope was evaluated in vitro with T lymphocytes from the cardiac tissue of patients with lesions arising out of rheumatic fever.07-22-2010
20100260682Compounds and methods of use thereof for assaying lysophospholipase D activity - Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening (HTS) for identification of potential inhibitors of lysoPLD activity.10-14-2010
20120034167TYROSINE KINASE RECEPTOR TYRO3 AS A THERAPEUTIC TARGET IN THE TREATMENT OF CANCER - The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.02-09-2012
20090117046METHODS FOR EVALUATING GENETIC SUSCEPTIBILITY AND THERAPY FOR CHRONIC INFLAMMATORY DISEASES - The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods of diagnosing and assessing predisposition to chronic inflammatory diseases. The present invention further provides methods for testing agents for effectiveness in treating and/or preventing diseases associated with chronic inflammatory or autoimmune conditions.05-07-2009
20100189655METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.07-29-2010
20100260680NOVEL BONE MASS INCREASING AGENT - The present invention provides an osteogenesis enhancer comprising a molecule capable of acting on RANKL that enhances differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts. A pharmaceutical composition for treatment or prevention of bone metabolism diseases associated with osteopenia, which comprising, as an active ingredient, a compound that acts on RANKL located on osteoblasts or cells capable of differentiating into osteoblasts and promotes differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts is provided.10-14-2010
20100189654ANIMAL MODEL FOR EVALUATING VASOMOTOR RESPONSE IN VIVO - A method for evaluating the effect of a compound on vasomotor response in vivo comprises the steps of administering said compound to a rabbit and measuring the diameter of the vessel lumen of a central ear artery of said rabbit in comparison with the baseline diameter of the vessel lumen of said central ear artery of said rabbit, said baseline diameter being measured prior to the administration of said compound.07-29-2010
20100260681ADRENOCORTICOTROPIC HORMONE ANALOGS AND RELATED METHODS - ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.10-14-2010
20100021386Treatment, prevention,and reversal of alcohol-induced liver disease - This invention relates to methods for treating, preventing, or reversing liver disease or damage produced by chronic alcohol intake by administering at least one peroxisome proliferator activated receptor (PPAR) agonist.01-28-2010
20100215584COMPOSITIONS AND METHODS OF MODULATING THE TASTE AND SMELL RECEPTORS AND SCREENING METHODS THEREFORE - The present invention relates to modulation of the perception of either taste or smell through modulation of the activity of GRKs which regulate the desensitization process of the taste and smell receptors. By the process of either inhibiting or enhancing GRK activity at the receptor site a modulation in perception of taste and smell can be achieved. The invention discloses methods of treatment as well as methods of discovering compounds useful in the invention. The invention further discloses methods of treating eating disorders or obesity using compositions of the type disclosed in the invention.08-26-2010
20100183520NETRIN-1 AS A BIOMARKER OF INJURY AND DISEASE - Detection and diagnosis of injury and/or disease in a subject can be key to preventing irreversible damage and death. Methods of aiding detection and assessment of a disease or condition in a subject are which include assaying netrin-1 protein and/or nucleic acid in a test sample obtained from the subject. Methods of assessment of treatment of a disease or condition in a subject are provided which include assaying netrin-1 protein and/or nucleic acid in a test sample obtained from the subject. Disclosed methods allow for earlier detection of renal dysfunction compared to currently available technology.07-22-2010
20100226857TUMOR CELL DIFFERENTIATION AGENTS AS CHEMICAL INHIBITORS AND TREATMENTS FOR INTRACELLULAR PARASITES - The present invention provides new compositions and methods for treatment of intracellular parasites. The compositions comprise one or more hydroxamic acids in an amount sufficient to interfere with the activity of one or more histone deacetylases in the intracellular parasites. The compositions and methods can be used to treat members of the Apicomplexa group of intracellular parasites.09-09-2010
20100150841Use of Tumor Necrosis Factor-Alpha P75 Receptor for the Reduction of Inflammation - As described below, the present invention features compositions and methods for increasing TNFR2/p75 receptor signaling to reduce inflammation. Methods for increasing TNFR2/p75 expression or signaling may also be used to increase the survival of resident cells or transplanted stem cells (e.g., bone marrow derived or peripheral blood derived stem cells) in a damaged tissue.06-17-2010
20100226858METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION - The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.09-09-2010
20100239501GENE SENSITIVE TO BONE/JOINT DISEASE AND USE THEREOF - The present invention provides a suppressing agent for inflammatory cytokine expression in joints and/or joint destruction (e.g., articular cartilage destruction) and/or pain in a bone/joint disease, comprising a substance that suppresses the expression or activity of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:2, a screening method for a substance that regulates inflammatory cytokine expression in joints and/or joint destruction (e.g., articular cartilage destruction) and/or pain in a bone/joint disease, comprising using the protein or a partial peptide thereof, and a diagnostic method for genetic susceptibility to a bone/joint disease, comprising detecting a polymorph in the base shown by base number 24007 in the partial base sequence of the human EDG2 gene shown by SEQ ID NO:3.09-23-2010
20100254907METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY - The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.10-07-2010
20100221186BIOMARKERS FOR CARDIOVASCULAR SIDE-EFFECTS INDUCED BY COX-2 INHIBITORY COMPOUNDS - Cardiovascular tissue mRNA expression profiles in monkeys treated with coxibs was analyzed. Genomic data indicated that the animals showing vasculitis exhibit a specific mRNA expression pattern. The pattern includes gene expression changes involved in blood and endothelial cell (EC) activation, interaction of blood cells with EC, activation of INFγ pathway, and release of pro-inflammatory cytokines and chemo-attractants. These results provide direct evidence of minimal vasculitis together with corresponding genomic signature and peripheral biomarkers for minimal vasculatis. These results also suggest that treatment might triggers/aggravate a clinically latent cardiovascular disorder in the context of an endothelium tropic viral infection and/or an autoimmune vascular disorder. The histopathological examination revealed marginal vascular changes consistent with the genomic findings. Measurement of soluble proteins present in serum and plasma using a multiplex assay were in line with the genomic results, showing the increased level of INFγ inducible proteins, increased expression of CXCL10 chemokine was confirmed by an ELISA both in serum and plasma. Use of these peripheral biomarkers allows a safe usage of cox-2 inhibitory compounds in clinics and selection of cox-2 inhibitory follow-up compounds with no cardiovascular toxicity. These data together with biochemical and histopathological findings suggest that the specific cox2 inhibitor may exaggerate host immune response during some specific viral infections with endothelial tropism, or subjacent vascular autoimmune disorders.09-02-2010
20100221187TREATMENT OF AMYLOIDOGENIC DISEASES - The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.09-02-2010
20100119452SCREENING METHOD - It is intended to provide a screening method of a compound having an effect of inhibiting the production of a prostatic specific antigen and/or an effect of suppressing the proliferation of androgen-independent prostatic cancer, comprising using an androgen-independent human prostatic cancer cell.05-13-2010
20100202973MICRORNA MOLECULES ASSOCIATED WITH INFLAMMATORY SKIN DISORDERS - This invention relates to the finding that inflammatory skin disorders, such as psoriasis and atopic eczema, are characterized by changes in the expression of specific microRNA molecules (miRNAs). These miRNAs may therefore be useful as biomarkers for inflammatory skin disorders as well as therapeutic targets. Methods of diagnosis and treatment of inflammatory skin disorders are provided, as well as methods of screening for therapeutic compounds.08-12-2010
20090074667DIAGNOSTIC METHODS FOR THE DETECTION OF RISK OF NEURODEVELOPMENTAL DISORDERS - The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.03-19-2009
20110236318ANIMAL MODEL OF AN EJACULATION-LIKE REFLEX - An animal model of an ejaculation-like reflex, wherein the ejaculation-like reflex is induced by continuous infusion of saline through a catheter extending into the proximal urethra of a non-human male animal, and wherein the urethra of the animal is occluded by extending and bending the penis at the base; and a method of screening a test substance for effectiveness in prevention or treatment of male ejaculatory dysfunction using the animal model.09-29-2011
20110027186TAZ/WWTR1 FOR DIAGNOSIS AND TREATMENT OF CANCER - We provide an anti-TAZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of TAZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of TAZ in the cell.02-03-2011
20110027185Methods of Screening for Anti-Angiogenic Compounds - The present invention relates to methods of screening for agents that bind to FBP21. In particular the present invention provides a method of identifying anti-angiogenic agents by screening for agents which are able to bind to FBP21. Compounds identified using the methods and screens of the present invention are useful in the prevention and treatment of conditions associated with angiogenesis.02-03-2011
20090110639PREDICTING VACCINE EFFICACY - The present invention provides methods for evaluating a vaccine, combinations of tests and reaction mixtures that can be used as part of such methods, and collections of results comprising results obtained from such methods. The methods, combinations, and collections are useful for determining whether a vaccine is effective and, for example, for comparing the efficacy of different vaccines.04-30-2009
20130129629MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES - The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.05-23-2013
20110129423ANTICANCER COMPOUNDS AND SCREENING METHOD - The invention provides a method to identify or characterize compounds for treating cancer wherein the compounds have a capacity to decrease systemic levels of one or more cholesterol metabolites in treated mammal(s). Such compounds include 17-(3-pyridyl)androst-5,16-diene-3β,7β-diol, 17-(2-morpholinyl)-7β-ethylandrost-5,16-diene-3β-ol, 17-(2-morpholinyl)-7β-ethylandrost-5,16-diene-3β-ol-16-acetate, 17-(4-oxazolyl)-7β-ethylandrost-5,16-diene-3β-ol-16-methyl ether and 17-(4-oxazolyl)-7β-ethylandrost-5,16-diene-3β-ol. Compositions and formulations comprising the compounds and one or more excipients are also provided.06-02-2011
20090068110ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR RECEPTOR - The invention provides various antibodies that bind to insulin-like growth factor-I receptor (IGF-1R), methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, cancer or aging. The antibodies include murine, chimeric, and humanized antibodies.03-12-2009
20110008259MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.01-13-2011
20090035221Methods and Compositions for Treatment of Erectile Dysfunction - A dosage chart for the treatment of achieving and maintaining male erectile response regardless of state of mind, occurrence of ejaculation or lack of sexual arousal of an object. The chart including a general, physical, and psychological conditions of the object; an age of the object; at least one pharmaceutical composition of one or more erection-producing agents; and a first corresponding dosage of the pharmaceutical composition to the age group and the general, physical, and psychological conditions of the object. The dosage chart further including observation of the object after receiving the corresponding dosage; and adjustment of a second dosage of the pharmaceutical composition.02-05-2009
20090035220 HIGH THROUGHPUT SCREENING SYSTEM AND METHOD - A high throughput screening method for determining the pharmacological effect of a given agent, the method comprising, providing an assay plate with at least one sample well, where at least one well contains a volume of media and at least one zebrafish, introducing at least one agent to at least one of the wells with the media and zebrafish and incubating for a given amount of time, providing an electrical stimulus to the plate so as to promote a locomotor response in the zebrafish, and detecting the locomotor response of the zebrafish in response to the electrical stimulus in each well an agent was added to relative to a control well. Also disclosed is an assay plate that includes a first electrode located substantially at the center of the bottom portion of the well and a second electrode located substantially around the circumference of the well wall.02-05-2009
20110033388IMAGEABLE RODENT MODEL OF ASTHMA - An imageable rodent model for asthma is described. The invention provides a rodent model for asthma wherein a rodent is provided with fluorescently labeled lymphocytes sensitized to an allergen which can be monitored after inducing an asthmatic response by the allergen. Methods to monitor trafficking of the fluorescently labeled cells in the rodent model for asthma are provided. Methods to determine the effectiveness of candidate drugs that regulate asthmatic responses using the rodent asthma model are also provided.02-10-2011
20110033387METHOD OF DETERMINATION OF PDH ACTIVITY AND IMAGING MEDIA FOR USE IN SAID METHOD - The invention relates to a method of determination of PDH activity by 02-10-2011
20110044907IN VIVO SCREENING ASSAYS - Disclosed herein are methods for identifying inhibitors of LOXL2 activity using in vivo assays. The assays include, for example, CCL02-24-2011
20110243853MODELS OF ERYTHROPOIESIS - Non human animal models are provided for diseases involving erythroid function, particularly myeloproliferative disease. The models are useful for testing and screening of biologically active agents that affect erythropoiesis, and erythroid function. In the animal models of the invention, a hematopoietic stem or progenitor cell (HSC) population that has been genetically altered by the introduction of a mutant JAK2 coding sequence is transplanted into an immunocompromised, xenogeneic, non-human recipient. The recipient animal is engrafted with the cell population at a high frequency, and develops a myeloproliferative disorder characterized by polycythemia.10-06-2011
20110044908Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration - The present invention provides methods for treating or limiting development of age-related macular degeneration, as well as methods for identifying compound suitable for such use.02-24-2011
20100150840Small-molecule agonists for type-2 orexin receptor - Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.06-17-2010
20100150839Compositions and Methods for Modulating Cognitive Function - The present invention provides compositions and methods for modulating, e.g., enhancing, cognitive function. The methods involve modulation of translation, modulation of a MAPK signaling pathway, or both. The invention further provides screening methods useful in identifying compounds that modulate, e.g, enhance, cognitive function. The invention further provides method of treating a subject to modulate cognitive function.06-17-2010
20110243854Methods and systems for identifying modulators of longevity - Methods of treating disorders such as neurofibromatosis-1 are provided, including methods in which catalytic antioxidants such as metalloporphyrins are administered. Methods of regulating longevity, and methods and systems for screening for modulators of aging or longevity, are also provided. In addition, related transgenic animals are described.10-06-2011
20090068111METHODS OF IDENTIFYING LEAD COMPOUNDS THAT MODULATE TOXICITY OF NEUROTOXIC POLYPEPTIDES - Methods of screening candidate agents to identify lead compounds for the development of therapeutic agents for the treatment of a neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease and methods for identifying a mutation in, or changes in expression of, a gene associated with neurodegenerative disease, such as Huntington's Disease and Parkinson's Disease, are provided.03-12-2009
20110091387METHODS AND COMPOSITIONS FOR REDUCING SKIN DAMAGE - The RhoE GTPase pathway has been identified as a target for screening and treatment methods for the prevention and/or reduction of short- and long-term UVB-induced skin damage, e.g., the prevention and/or reduction of UVB-induced wrinkles. The invention thus features screening and treatment methods for prevention or reduction of UVB-induced sin damage, and related compositions, e.g., cosmetic compositions.04-21-2011
20090226374ANAPHYLATOXINS FOR DETECTING CLINICAL CONDITIONS - Non-allergic hypersensitivity reactions can be observed in a sample of cells from a subject in response to anaphylatoxins. Accordingly, methods are provided for detecting clinical conditions such as cellular hyper-reactivity, non-allergic hypersensitivity, asthma, inflammation, chronic or acute infection, bacterial infection, viral infection, parasite infection, adverse drug reaction, organ rejection, vasculitis, mastocytosis, eosinophilia, basophilia, leukemia, and/or C3a or C5a receptor defects in a subject. Also provided are kits for detecting such clinical conditions in a subject.09-10-2009
20090257955Sheep model of neuropathic pain behavior and uses thereof - Methods for producing peripheral nerve injury in sheep are provided. The sheep model provides a model of persistent neuropathic pain in humans. Methods for drug delivery are provided. Also provided is a method for screening potentially therapeutic agent for the treatment of persistent neuropathic pain. Also provided are the methods for measuring the changes produced by neuropathic pain.10-15-2009
20100055038Methods for Predicting Effectiveness of Apheresis Therapy for Heart Failure - An objective of the present invention is to provide methods for predicting the effectiveness of apheresis therapy in the treatment of dilated cardiomyopathy.03-04-2010
20100055037Treatment, prevention, and reversal of alcohol-induced brain disease - This invention relates to methods for treating, preventing, or reversing brain disease or damage produced by chronic alcohol intake by administering a peroxisome proliferator activated receptor (PPAR) agonist.03-04-2010
20090028794Uses and compositions for treatment of psoriatic arthritis - The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of psoriatic arthritis in a subject.01-29-2009
20090028795NOD1 as an Anti-Tumor Agent - The invention provides compositions and methods for treating tumors that involve increasing the expression of Nod1 and/or the activity of NOD1.01-29-2009
20110177001SCREENING ASSAY EMPLOYING DEX AND GDF8 - Certain aspects of this disclosure relate to a method that comprises contacting a mammalian cell with a glucocorticoid receptor ligand and a myostatin receptor ligand, thereby activating the glucocorticoid receptor and said myostatin receptor. A screening assay employing the same is also provided.07-21-2011
20100135911SPATIAL EVOLUTION OF NEURAL ACTIVITY - A method for identifying a candidate drug includes administering a test compound to test subjects and having the test subjects perform a sustained task. A first evolution of neural activity in the test subjects is then determined and compared with a second evolution of neural activity. This second evolution of neural activity is obtained from control subjects performing the sustained task in the absence of the test compound. The test compound is then designated to be a candidate drug when a difference between the first and second evolutions of neural activity is above a difference threshold.06-03-2010
20110150771CHIMERIC WEST NILE/DENGUE VIRUSES - The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.06-23-2011
20110250142COMBINATION THERAPIES FOR TREATMENT OF HYPERTENSION AND COMPLICATIONS IN PATIENTS WITH DIABETES OR METABOLIC SYNDROME - Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and a second antihypertensive agent (preferably a calcium antagonist, an ACE inhibitor, or an angiotensin II receptor antagonist) for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome.10-13-2011
20110250141Methods For Improving Skin Quality - A skin treatment regimen for delivery of a rinse-off personal skin care composition is provided. The rinse-off personal skin care composition includes varying ratios of a lathering agent to a hydrophobic benefit agent. The rinse-off personal skin care composition can be applied to skin of a user in phases over and/or in a treatment cycle. Each of the phases of the treatment cycle can include a ratio of the varying ratios that can be different such as higher or lower than a ratio of adjacent phase.10-13-2011
20110085981GLYCAN-BASED DRUGS, THERAPIES AND BIOMARKERS - The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed.04-14-2011
20110085982DKAT CELL LINE, A MODEL FOR HUMAN TRIPLE-NEGATIVE BREAST CANCER - The present invention provides a human triple-negative breast cancer cell line designated DKAT. The DKAT cell line has a marker profile of high expression of Snail-1 and Snail-2 (Slug); and a p53 mutation in exon 8 at codon 273 (CGT>CAT). The present invention further provides methods of using the DKAT cell line.04-14-2011
20110085984Drug Product and Process for Making - The invention provides a drug product for treating radiation exposure comprising, a drug in a dosage form; and packaging for the drug together with a package insert or label that includes information about the drug's efficacy, where the information about the drug's efficacy is obtained at least in part from methods described in the disclosure.04-14-2011
20110076236COMPOSITIONS AND METHODS OF TREATMENT USING MODULATORS OF MOTONEURON DISEASES - The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules in neurons); methods for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease; the discovery of drug agents that modulate neuronal microtubule dynamics in living subjects with motoneuron diseases; the discovery that administration of such agents, alone or in combinations, can improve MT-mediated transport of “synaptic vesicle cargo” molecules along and through axons; the discovery that such modulation of altered microtubule dynamics and improvement in MT-transport of molecules along axons can provide marked neuroprotective therapy for living subjects with motoneuron diseases, including delay in symptoms and prolongation of survival; and the discovery that monitoring of neuronal microtubule dynamics in response to therapeutic interventions in subjects with motoneuron diseases, allows diagnostic monitoring, to optimize therapeutic regimens and treatment strategies in individual subjects or in drug trials. The monitoring involves measuring isotope enrichment in secreted synaptic vesicle cargo molecules.03-31-2011
20110081296SYSTEMS AND METHODS FOR IDENTIFICATION OF CILIOPATHY THERAPEUTICS - The invention provides systems and methods for identifying therapeutic targets for treating a disease including a ciliopathy. The invention further provides for drug discovery, and animal model systems related to drug discovery. The invention further relates to therapy of genetic disorders of the cellular cilia or basal bodies.04-07-2011
20100047177METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES - Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuinAMPK activity, LKB 1 activity and/or CaMKKβ activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons, alone or in combination with agents that act by other mechanisms. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing such neuropathies.02-25-2010
20110150774SCREENING FOR MODULATORS OF CES1 AND/OR CES3 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the carboxylesterase 1 (CES1) and/or carboxylesterase 3 (CES3) proteins.06-23-2011
20110150769IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN - The present application provides methods and compositions that can be used to treat persistent pain and to identify compounds that can be used for treating persistent pain. More specifically, agonists of members of the Mrgpr receptor family, particularly agonists of MrgprX1, can identified and screened for use in treating persistent pain, such as pain caused by inflammation or nerve injury.06-23-2011
20120148495METHODS FOR TREATING NICOTINIC ACETYLCHOLINE RECEPTOR ASSOCIATED DISEASES - The present invention provides methods and compositions for treating subjects suffering from a disorder associated with a nicotinic acetylcholine receptor (nAChR), methods for treating a subject having a disorder that would benefit from an increase in neural plasticity, and methods for modulating the plasticity of the primary visual cortex in subjects by modulating the expression, stability, and/or activity of Lynx1.06-14-2012
20110256062Methods - A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method may comprise or further comprise the step of assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the subcellular location of LRRK2. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems.10-20-2011
20100278743METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES AND AMYLOID BETA AMYLOIDOSIS BY MODULATING CRF RECEPTOR SIGNALING - Methods for treating or preventing tauopathies and/or Aβ amyloidosis by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer's disease by administration of CRF-R1 selective antagonist are provided.11-04-2010
20100310466THIENOPYRANONES AS KINASE INHIBITORS - The invention, relates to compounds of formula I (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as PI-3 kinase.12-09-2010
20100297020PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT - Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.11-25-2010
20090010849Methods of screening an agent for an activity in an isolated eye of a teleost - The present invention provides methods of screening an agent for an activity in an isolated organ, e.g., eye, from a teleost, e.g., zebrafish. Methods of isolating eyes from zebrafish are provided. Methods of screening an agent for an ocular activity in the isolated eye are provided. Methods of screening an agent for an ocular activity in a model of ocular disease or disorder are provided. Methods of screening an agent for an ocular activity in the isolated eye and for screening the agent for cell death and/or toxic activity in the eye or other organ or tissue are provided. The invention further provides high throughput methods of screening agents for an activity in isolated eyes of zebrafish in multi-well plates.01-08-2009
20110150772MODULATORS OF CARNITINE OCTANOYLTRANSFERASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of carnitine octanoyltransferase (CROT), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.06-23-2011
20120171125Methods for Enhancing the Cognitive Function - A compound having an affinity to a SV2 protein for the treatment of a condition associated with enhancement or improvement of the cognitive ability or to counteract cognitive decline of a mammal. For example, a compound which is covered by formula (I) R07-05-2012
20120171124SCREENING METHODS FOR COGNITIVE ENHANCERS - The present invention provides methods for identifying cognitive enhancers able to enhance CREB pathway function. Cognitive enhancers identified in accordance with the invention can be used in rehabilitating an animal with cognitive dysfunctions and for enhancing memory or normal cognitive performance (ability or function) in a normal animal.07-05-2012
20120171123USES AND COMPOSITIONS FOR TREATMENT OF RHEUMATOID ARTHRITIS - The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.07-05-2012
20110158911Methods for Screening for Antibiotic Compounds - The present invention is a method for screening drugs for antibiotic activity by screening a drug for activity to disrupt a toxin-antitoxin complex in a bacterial cell.06-30-2011
20100003194INHIBITOR SCREENING METHOD AND ATOPIC DERMATITIS LIKE SYMPTOM INDUCING METHOD WHICH UTILIZES INDUCTION OF PRODUCTION OF INTERLEUKIN 18 BY KERATINOCYTE AND UTILIZATION OF SAME - The present invention provides methods which use induction phenomenon of production of interleukin 18 (IL-18) from keratinocyte (KC), and their usages. The methods are preferably applicable for understanding of pathogenic mechanisms of atopic dermatitis (AD) and AD-like symptoms, and for development of therapeutic drugs for AD and AD-like symptoms. For example, by applying, on skin of mice or the like, protein A (SpA) derived from 01-07-2010
20080247954Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment - The present invention provides for the treatment of primary headache disorders, particularly migraine, using antagonists of the EP10-09-2008
20080247956IDENTIFICATION OF NOVEL FACTORS THAT BLOCK PROGRAMMED CELL DEATH OR APOPTOSIS BY TARGETING JNK - Methods and compositions for modulating apoptosis by acting on the c-Jun-N-terminal kinase (JNK) pathway and assays for the isolation of agents capable of modulating apoptosis, including modulators of the JNK pathway are disclosed. A method of modulating JNK pathway independent of Gadd46β is disclosed. Methods and compositions are presented for the preparation and use of novel therapeutic compositions for modulating diseases and conditions associated with elevated or decreased apoptosis.10-09-2008
20080247955Inflammation treatment, detection and monitoring via TREM-1 - The present invention provides methods of treating inflammatory diseases/disorders in a subject by inhibiting/antagonizing TREM-1 expression/activity/signal transduction and/or DAP12/TyroBP expression and/or activity. Methods of detecting the presence of inflammatory disease in a subject by detecting TREM-1 and/or DAP12/TyroBP expression and/or activity in the subject or a sample obtained therefrom, wherein increased expression or activity is indicative of the inflammatory disease are also included. The present invention further provides methods for assessing the efficacy of a TREM-1-modulating agent administered to a patient by detecting levels of secreted phosphoprotein 1 (SPP1) and/or one or more other biomarkers in the patient or in a sample from the patient.10-09-2008
20110150776Method for Testing and Treating Delayed Food Allergies - A method for testing, treating, and preventing delayed food allergies includes: receiving detailed symptom, medical, and dietary histories from a patient; formulating a combination of one or more food extracts at selected concentration for sublingual adminstration over a trial period; determining whether the patient's symptoms have improved, worsened, or had no change, in response to the administration of the combination; and altering the combination in response to whether the patient's symptoms have improved, worsened, or not changed, so as to induce immune system food tolerance.06-23-2011
20110150773MODULATORS OF ACETYL-COENZYME A ACYLTRANSFERASE 1 OR 2 IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of acetyl-coenzyme A acyltransferase 1 (ACAA1) or of acetyl-coenzyme A acyltransferase 2 (ACAA2), and also utilizes modulators of the expression or of the activity of either of these enzymes, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.06-23-2011
20090324500SCREEN FOR INFLAMMATORY RESPONSE MODULATORS - The present invention relates to transgenic aquatic vertebrate organisms and methods of their use in screening for, or identifying agents that are useful in modulating the inflammatory response and particularly for identifying agents useful for treating inflammatory disorders.12-31-2009
20090317332HUMAN G PROTEIN-COUPLED RECEPTOR AND MODULATORS THEREOF FOR THE TREATMENT OF OBESITY AND CONDITIONS RELATED THERETO - The present invention relates to methods of using a G protein-coupled receptor (GPCR) to screen one or more candidate compounds as a modulator of body mass or of adiposity or of percentage body fat in a subject or as a pharmaceutical agent for obesity and conditions related thereto. Inverse agonists and antagonists of the invention are useful as therapeutic agents for the prevention or treatment of obesity and conditions related thereto, including hypertension, insulin resistance, metabolic syndrome, Type 2 diabetes, dyslipidemia, atherosclerosis, coronary heart disease, and stroke. Agonists and partial agonists of the invention are useful as therapeutic agents for the prevention or treatment of disorders ameliorated by increasing body mass including, but not limited to, cachexia.12-24-2009
20110150775GENOMIC APPROACHES TO FETAL TREATMENT AND DIAGNOSIS - The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods for Down Syndrome involving, in some embodiments, gene expression analyses of fetal RNA and/or detection of expression of particular genes involved in Down Syndrome. Also provided are microarrays and kits useful in prenatal diagnostic applications.06-23-2011
20090297453DIAGNOSTIC PROCEDURES USING DIRECT INJECTION OF GASEOUS HYPERPOLARIZED 129XE AND ASSOCIATED SYSTEMS AND PRODUCTS - A method of screening for pulmonary embolism uses gaseous phase polarized 12-03-2009
20080311043Uses and compositions for treatment of psoriatic arthritis - The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of psoriatic arthritis in a subject.12-18-2008
20080311044Methods of determining hair follicle inductive properties - The present invention provides a method for determining hair inductive properties of a composition comprising injecting a composition comprising dissociated dermal cells and epidermal cells into skin of a mammal and determining whether at least one hair follicle forms.12-18-2008
20080267880AUTOMATED METHOD FOR HIGH THROUGHTOUT SCREENING OF NEMATODES - This invention provides a high throughput survival assay, using uptake of a marker dye (e.g. a fluorescent dye) as a marker of death of a nematode. The assay permits high throughput screening of thousands of compounds possible. By the application of automated worm handling technology we are able to accurately dispense nematodes into 384 well microtitre plates, at rates many thousand of times faster than previously possible. In addition, we have automated the analysis of survival by the use of a fluorometric plate reader that quantitates the degree of fluorescence within each well.10-30-2008
20110256061Binding agents to the Integrin Alpha-11 subunit, and uses thereof - The present invention relates to an antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, for use in medicine, wherein the antibody or antigen-binding fragment, variant, fusion or derivative thereof has binding specificity for an integrin α11 subunit, or a heterodimer thereof. In particular, the invention relates to the use of such antibodies or antigen-binding fragments, variants, fusions or derivatives thereof, in the treatment of inflammatory disorders such as arthritic diseases (e.g. rheumatoid arthritis and osteoarthritis).10-20-2011
20080219931Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies - The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.09-11-2008
20080219930Method for the evaluation of dengue virus therapeutic agents - The inventive subject matter relates to a method for evaluating potential compounds and vaccines for the prevention or treatment of dengue virus infection. The method utilizes pigs as an animal model for the evaluation of test vaccine or drug compounds. The breeds that can be utilized and in the inventive method include Yorkshire or Lancashire as well as miniature pig breeds.09-11-2008
20110165082METHOD FOR DETERMINING THE ANTI-TUMOR EFFICACY OF MONOCLONAL ANTIBODIES - The present invention relates to a method for determining the anti-tumor efficacy of monoclonal antibodies in pre-clinical rodent testings and the use of said method for the reduction of side testings.07-07-2011
20110165081PSMA ANTIBODIES AND USES THEREOF - The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.07-07-2011
20110020232CANCER TREATMENT WITH GAMA-SECRETASE INHIBITORS - Provided are methods for treating cancer in a patient, comprising administering to a patient in need thereof a therapeutically effective regimen, the regimen comprising administering a gamma-secretase inhibitor, wherein the regimen results in a reduction in the cancer cell population in the patient. In some embodiments of the methods, the therapeutically effective regimen stabilizes, reduces or eliminates the cancer stem cell population.01-27-2011
20110027184PROTEIN C PATHWAY ASSOCIATED POLYMORPHISMS AS RESPONSE PREDICTORS TO ACTIVATED PROTEIN C OR PROTEIN C-LIKE COMPOUND ADMINISTRATION - The invention provides methods, nucleic acids, compositions and kits for predicting a subject's response to treatment with activated protein C or protein C like compound to identify subjects having a greater benefit from treatment with activated protein C. The method generally comprises determining a protein C pathway associated gene polymorphism genotype(s) of a subject for one or more polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response polymorphism to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with activated protein C or protein C like compound and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with an anti-inflammatory agent or anti-coagulant agent based on the subject's genotype.02-03-2011
20100284927USE OF MRI CONTRAST AGENTS FOR EVALUATING THE TREATMENT OF TUMORS - Described herein are methods for using macromolecular MRI contrast agents to evaluate the effectiveness of anti-cancer treatments. The methods take advantage of MRI for evaluating more specifically and accurately one or more tumor properties of the tumor in response to a particular treatment. Ultimately, the 5 methods described herein help evaluate the effectiveness of the anti-cancer treatment over time.11-11-2010
20100284926USE OF G-CSF FOR THE TREATMENT OF STROKE - The invention relates to the use of G-CSF for the treatment of cerebral stroke, particularly cerebral stroke with a large baseline infarct volume. Administration of G-CSF at a total dose of 30 to 180 μg per kg body weight over a treatment period of about 3 days is suitable for the treatment of stroke. Treatment in accordance with the invention with a total dose of 80 to 150 μg per kg body weight is preferred.11-11-2010
20110262361 EFFECTIVE NEW DRUG TARGET FOR THE TREATMENT OF TUBERCULOSIS - The present invention allows a screening method for identifying novel drugs for the treatment of tuberculosis as well as a diagnostic method for identifying clinical strains that are resistant to these novel drugs. In particular, the present invention relates to a method for screening in vitro drug candidates for the treatment of tuberculosis by interfering with the arabinogalactan biosynthesis, the said method comprising a step of putting into contact a 10-27-2011
20110262360Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof - Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenol-modified opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the phenol-modified opioid prodrug so as to modify enzymatic cleavage of the phenol-modified opioid prodrug.10-27-2011
20110262359COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF - The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.10-27-2011
20110135574METHODS OF TREATING KIDNEY DISEASE - It has been discovered that TRPC5 activity abolishes actin stress fibers and diminishes focal adhesion formation, rendering a motile, migratory podocyte phenotype. This invention relates generally to methods of reducing expression or activity of TRPC5 to treat, or reduce risk of developing, kidney disease, e.g., proteinuria, in a subject.06-09-2011
20100297018Prognosis and therapy of liver failure - A method for assessing prognosis in an individual suffering from liver failure, which method comprises detecting endotoxin in the individual, for example by determining the neutrophil function in the individual. The method can be used to determine whether there is an increased risk of infection in the individual, an increased risk of organ failure in the individual, an increased risk of mortality in the individual and/or an increased risk that the individual will not respond positively to treatment with an immunosuppressive agent, a steroid or an antibiotic.11-25-2010
20110052502MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof - Methods and compositions for the diagnosis, prognosis and/or treatment of leukemia associated diseases are disclosed.03-03-2011
20110052501POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development.03-03-2011
20110052500TAJ in Neuronal Function - The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.03-03-2011
20110052499BABOON HOMOLOG OF HUMAN CD147 - Polynucleotide sequences encoding a baboon homolog of human CD147 and polypeptides obtainable form the polynucleotides and uses are disclosed.03-03-2011
20100239500SUBSTITUTED TRIAZINE COMPOUNDS FOR NERVE REGENERATION - A family of substituted triazine compounds is synthesized by combinatorial solid phase chemistry. These compounds were found to increase the growth of neurons/axons from central nervous system neurons that had been damaged, and can be used in methods and pharmaceutical compositions for treating injuries, diseases and conditions associated with nerve damage.09-23-2010
20100329986Adult Hepatic Progenitor Cells and Methods of Use Thereof - Compositions and methods effective for identifying, isolating, and utilizing adult hepatic progenitor cells are provided.12-30-2010
20100329985TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES - The present invention relates to the use of fragments of heat shock proteins for the treatment and/or prevention of autoimmune diseases such as arthritis or inflammatory diseases such as Inflammatory Bowel Diseases. Preferably bacterial and/or mammalian heat shock proteins belonging to the HSP70 families are used.12-30-2010
20110256064Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins - The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.10-20-2011
20090202439Methods for treatment of angiogenesis - The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration to a subject one or more compounds that alter the activity of VEGF pathway members, including LacCer synthase (GalT-V/VI), PECAM1, VEGFR, VEGF or related pathway members to treat a subject suffering from or susceptible to a condition caused or contributed to by VEGF. The present invention also relates to methods for detecting and analyzing compounds with therapeutic capacity to treat such condition.08-13-2009
20100166661siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION - No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of β-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus.07-01-2010
20100158809TRUNCATED PAP2 AND METHODS OF MAKING AND USING SAME - A method of treating pancreatitis is provided, including the steps of: providing a mammal having pancreatitis; and administering a therapeutically effective amount of a truncated N-terminal PAP2; and making of an antibody specifically directed to detect PAP2.06-24-2010
20100158807RECEPTOR - We disclose a method of treating or preventing a disease selected from the group consisting of: a bladder disease, a bladder disorder, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, including overflow and urge incontinence, urinary urge, cystitis, including interstitial cystitis and overactive bladder.06-24-2010
20100196279TREATMENT OF GAUCHER DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARKERS - Provided is a method of monitoring the treatment of Gaucher disease with specific pharmacological chaperones using systemic and/or cellular surrogate markers. Also provided is a new biomarker that may be used to monitor the progress of such treatment.08-05-2010
20120121514NEEDLE ARRAY ASSEMBLY AND METHOD FOR DELIVERING THERAPEUTIC AGENTS - A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.05-17-2012
20100068146Method for Improving Brain Fitness with Consumable Products - The present invention is directed to a method for improving brain fitness. The method includes the step of providing non-protein amino acid to a consumer prior to playing a brain game.03-18-2010
20100068148ENHANCED RESOLUTION OF TUMOR METASTASIS USING A SKIN FLAP MODEL - A enhanced method for observing tumor progression, angiogenesis and/or metastasis in animal models in real time is described. The invention employs a skin flap over the area to be observed that can be opened and closed reversibly. The invention also permits simultaneous observation of more than one tumor by use of multiple colors.03-18-2010
20100040550RADIOLABELLING METHODS - The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I): with a compound of formula (II) or, a compound of formula (III): with a compound of formula (IV): in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.02-18-2010
20090175796ANTIBODIES AND RELATED MOLECULES THAT BIND TO 24P4C12 PROTEINS - Antibodies and molecules derived therefrom that bind to 24P4C12 protein and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.07-09-2009
20090175795CHIMERIC THERAPEUTIC AGENTS - A fusion protein including (i) a first segment that is located at the amino terminus of the fusion protein and contains the sequence of a first biological active peptide or protein; and (ii) a second segment that is located at the carboxyl terminus of the fusion protein and contains the sequence of a second biological active peptide or protein. The first and second segments are operably and covalently linked. Also disclosed are nucleic acids encoding the fusion protein, vectors and host cells having the nucleic acids, and related composition and methods of treating diabetes or/and obesity.07-09-2009
20100189653Pyrone analogs for therapeutic treatment - Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof. Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents. Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment. Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.07-29-2010
20110189099ATTENUATED MYCOPLASMA GALLISEPTICUM STRAINS - The present invention provides live, attenuated 08-04-2011
20110189098THERAPY DELIVERY AND MONITORING USING A GENE OF INTEREST-REPORTER FUSION PROTEIN AND OPTICAL IMAGING - The present invention relates to a method of non-invasively monitoring the expression of a gene of interest in a cell when contacting said cell with a compound influencing the expression of said gene of interest. The present invention is also concerned with different isolated nucleic acid molecules comprising a coding sequence. Said coding sequence comprises a gene of interest-sequence encoding a gene of interest-polypeptide fused to a reporter sequence encoding a fluorescent reporter polypeptide and is operatively coupled to a promoter sequence. The present invention is also concerned with the use of a method and a nucleic acid molecule of the invention for delivering a compound influencing the expression of a gene of interest in a cell, monitoring the delivery of said compound as well as monitoring the influence on the expression of said gene fluorescence of interest induced by said compound at the same time.08-04-2011
20110189097Use of WNT inhibitor to inhibit angiogenesis in the CNS - Activation of the Wnt signaling pathway in cells is inhibited by contacting the cells with an Apcdd peptide. Wnt inhibition by this and other methods finds particular use in treating Wnt-mediated disease conditions such as conditions associated with aberrant angiogenesis in the CNS or aberrant cell proliferation.08-04-2011
20110150770MULTIVALENT VACCINE AGAINST PORCINE TESCHOVIRUS AND OTHER DISEASE CAUSING ORGANISMS IN SWINE - An immunogenic composition or vaccine, and method of treatment are provided by the present invention. The immunogenic composition is useful for treating, preventing, and lessening the severity of clinical symptoms associated with disease-causing organisms in swine, utilizing one or more Porcine Teschovirus antigen(s) along with an antigen of the other disease-causing organism in swine and a pharmaceutically acceptable carrier.06-23-2011
20120308483Treatment of Sleep Disturbances - The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.12-06-2012
20120308482Monkey Homolog of Human Interferon Omega - Cytokine IFNω nucleic acids from the Cynomolgus monkey are useful for expression of IFNω proteins that are functional homologs of human IFNω. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of IFNω, the generation and testing of IFNω modulators and related activities.12-06-2012
20100272648Methods of Identifying Improved NMDA Receptor Antagonists - Processes are provided for the identification a compound that is useful to treat or prevent a disorder that lowers the pH in a region of affected tissue comprising assessing the difference in potency, or potency boost, of the compound at physiological pH versus disorder-induced pH in a cell that expresses a human NMDA receptor. The assessment of potency boost can include measuring an IC10-28-2010
20090123380METHOD OF ASSAYING SATIETY ENHANCING TASTANTS - Compositions for enhancing satiety and weight loss in an individual, assays for assessing a tastant for enhancing satiety and weight loss, and methods of using the composition to suppress appetite and enhance weight loss are provided.05-14-2009
20110064671MODULATION OF BLOOD BRAIN BARRIER PERMEABILITY - The present invention relates to a method of increasing blood brain barrier permeability in a subject. This method involves selecting a subject who would benefit from increased blood brain barrier permeability and subjecting the selected subject to a treatment. That treatment increases adenosine level and/or bioavailability, modulates adenosine receptors, and/or increases CD73 level and/or activity under conditions effective to increase blood brain barrier permeability in the subject. Methods of decreasing blood brain barrier permeability in a subject, treatment of a subject for a disorder or condition of the central nervous system, and screening compounds effective in increasing blood brain barrier permeability, as well as pharmaceutical agents are also disclosed.03-17-2011
20090238762Method for treating joint damage - Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.09-24-2009
20110085980CELL CYCLE REGULATION AND DIFFERENTIATION - The present invention provides compositions and methods for regulating neural cell proliferation or differentiation. The present invention also provides methods for selecting for bioactive agents effective in regulating proliferation or differentiation.04-14-2011
20090074666Peptide vaccine for influenza virus - The invention relates to the method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus. The invention also provides peptide epitopes for use in the prevention and/or treatment of influenza or for the development of such treatment or vaccine against influenza.03-19-2009
20090074668Vldlr-/- mouse models and related methods - A Vldlr−/− mouse model and related methods has been shown to be an effective model for eye-disease studies and determination of effective therapeutics. Vldlr−/− mice are observed having both chorodial neovascularization coupled with subretinal deposits and photoreceptor atrophy. The mice of the present disclosure have knocked out the very low-density lipoprotein receptors. Similarly, methods of determination of effective therapeutics for age-related macular degeneration are disclosed herein.03-19-2009
20100284925Small Molecule Intervention for Obesity - Methods and compositions for activating PLTP gene expression include administering an effective amount of a limonoid.11-11-2010
20120148497Methods of using field-derived colonies of insects selected for decreased susceptibility to plants expressing insecticidal toxins - Methods are provided for using field-derived colonies of insects that comprise field-evolved resistance to insecticidal toxins that are produced in transgenic plants. The methods find use in resistance management strategies for transgenic crop plants expressing insecticidal toxins.06-14-2012
20100278741Novel compositions including sphingosine kinase type 1 inhibitors, and processes for using same - Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).11-04-2010
20080206144MDR1 VARIANTS AND METHODS FOR THEIR USE - This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an mdr1 truncation.08-28-2008
20090269282Methods for treating, preventing and diagnosing procine ttv infection - Compositions and methods for treating, preventing and diagnosing Torque teno virus (TTV) infection in pigs are disclosed. Also described are methods of identifying compounds for the treatment and prevention of TTV infection, as well as TTV animal models and methods of producing the same.10-29-2009
20110110862DISEASE ANIMAL MODEL FOR CHRONIC PAIN - A disease animal model, characterized in that a chronic pain is induced by applying a treatment for reducing the biogenic amine level to a mammal, and a method for screening for a therapeutic agent for a chronic pain, characterized in that a test substance is administered to said disease animal model.05-12-2011
20090297451INFECTION MODEL FOR DEVELOPING CHEMOTHERAPEUTIC AGENTS - The present invention relates to a small animal model useful in identifying novel therapies for treating pathogenic diseases. This flexible biotechnology tool is valuable for developing novel chemotherapeutics for a broad range of microbial pathogens.12-03-2009
20120039812GENES ASSOCIATED WITH POSTTRAUMATIC-STRESS DISORDER (PTSD) - The present invention relates to a method of identifying a predisposition for developing posttraumatic stress disorder (PTSD) in a subject comprising assessing in a sample obtained from said subject the expression level of one or more genes selected from the FK506 binding protein 5 (FKBP5) gene, the signal transducer and activator of transcription (STAT5B) gene and the nuclear factor I/A (NFIA) gene, wherein a decrease in the expression level of said one or more genes as compared to the expression level of the corresponding gene(s) of a control is indicative of a predisposition for developing PTSD. Further, the invention relates to a method of identifying a compound capable of preventing or treating PTSD or capable of serving as a lead compound for developing a compound capable of preventing or treating PTSD and also to a method of selecting a therapy to prevent or treat PTSD.02-16-2012
20120148498Compositions and Methods for the Systemic Treatment of Arthritis - The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.06-14-2012
20120148496Method of Altering Reaction Time - Methods and compositions for modifying an individual's reaction time to an external stimulus are disclosed.06-14-2012
20090274626TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY - The invention provides methods for modulating tumor cell proliferation by contacting cells (e.g. tumor cells) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor. Additionally, methods for treating cancer and methods for identifying TACE inhibitors is also provided.11-05-2009
20110059021PROCESS FOR PREPARING VARIANT OF ERYSIPELOTHRIX RHUSIOPATHIAE SURFACE PROTECTIVE ANTIGEN IN E. COLI - A variant of 03-10-2011
20110064670METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER AGENT - The invention provides methods for identifying patients having an increased likelihood of responding to an anti-cancer agent or an increased likelihood of undergoing metastasis. The invention also provides methods for monitoring a patients' response to an anti-cancer agent. The invention also provides kits and articles of manufacture for use in the methods.03-17-2011
20110064668J-SUPERFAMILY CONOTOXIN PEPTIDES - The invention relates to relatively short peptides (termed J-Superfamily conotoxin peptides, J-conotoxins or J-conotoxin peptides herein), about 25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The J-conotoxins are useful for treating disorders involving voltage gated ion channels and/or receptors.03-17-2011
20110064672Articles and Compositions for Enhancing Sports Scores - Methods and compositions for enhancing the score of an individual in a sport activity are disclosed.03-17-2011
20110064669USE OF GALANIN IN A METHOD OF TREATING NEURODEGENERATIVE DISEASES OR CONDITIONS - The present invention relates generally to a method for the treatment and prophylaxis of neurodegenerative diseases and conditions. More particularly, the present invention contemplates the treatment or prophylaxis of neurological conditions involving oligodendrocyte cytotoxicity or cell cycle arrest, demyelination and/or axonal or neuronal degeneration. Agents, medicaments and pharmaceutical compositions useful in the treatment and prophylaxis of neurodegenerative conditions and disorders also form part of the present invention.03-17-2011
20110318271Arginase Inhibitors for the Treatment of Depression - The subjects of the current invention are compounds, which exhibit arginase inhibiting activity (including difluoromethylornithine (DFMO) and L-norvaline, but not limited to them), and which can be used as therapeutically active agents for the treatment and prevention of depression and/or depression-related conditions. Other subjects of the present invention are the use of said arginase inhibiting compounds as therapeutically active agents for the manufacture of pharmaceutical compositions for human and veterinary application, pharmaceutical composition comprising said arginase inhibiting compound and a method for treatment and prevention of depression and/or depression-related conditions. Also, a method for identifying compounds suitable for use as therapeutically active agents for treatment and/or prevention of depression and/or depression-related conditions is disclosed. The invention further comprises a kit for selecting compounds for treatment and/or prevention of depression and/or depression-related conditions.12-29-2011
20110318272PESTICIDAL MIXTURES GIVING SYNERGISTIC PESTICIDAL EFFECTS - Compositions and methods are provided for synergistic pesticidal mixtures comprising a first pesticidal composition and a second pesticidal composition, wherein the pesticidal activity of the mixture exhibits synergistic effects compared with the expected effects of the mixtures based on the sum of the activity of the first pesticidal composition alone and the activity of the second pesticidal composition alone, wherein the pesticidal activity of the mixture allows the use of lower amounts of each component to achieve a desired level of control of the target pest, and/or provides a desired level of control of the target pest sooner after application of the mixture, compared with the amount and/or time required for first pesticidal composition alone, and the amount and/or time required for the second pesticidal composition alone, to achieve the same level of control. Synergistic pesticidal mixtures and methods according to the invention are provided comprising a first pesticidal composition comprising at least two essential oils, a carrier oil, and an emulsifier, and a second pesticidal composition comprising at least one insecticide, wherein the pesticidal activity of the mixture is greater than the sum of the activity of the first pesticidal composition alone and the activity of the second pesticidal composition alone. Methods are provided for screening and identifying synergistic pesticidal mixtures according to the invention.12-29-2011
20120003158Biomarkers for Inflammatory Bowel Disease and Methods Using the Same - The present invention provides various biomarkers of inflammatory bowel disease, including biomarkers for Crohn's disease and biomarkers for Ulcerative colitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods for distinguishing between inflammatory bowel diseases, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, methods of assessing efficacy of compositions for treating inflammatory bowel disease, methods of screening compositions for activity in modulating biomarkers of inflammatory bowel disease, methods of treating inflammatory bowel disease, as well as other methods based on biomarkers of inflammatory bowel disease.01-05-2012
20100021387Methods for Inducing Reversible Stasis - The present invention concerns compositions and methods involving incubating biological materials under hypoxic or anoxic conditions to induce stasis or suspended animation. Methods of screening for compounds that induce stasis or compounds that increase the ability to undergo stasis are included. Such methods have ramifications for preserving biological materials as well as reducing or preventing trauma to biological materials. Also contemplated are methods for screening compounds that are active or more active under hypoxic conditions than normoxic conditions. Such methods can be used to identify antitumor compounds that would operate under hypoxic conditions in which tumor cells survive.01-28-2010
20120301404TREATMENT OF CACHEXIA - The invention characterizes and provides a receptor for Proteolysis Inducing Factor (PIF) and associated methods and materials employing the same. These have utility, for example, in the provision of treatments for cachexia.11-29-2012
20120301403POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS - Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds are also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans.11-29-2012
20120301402RAP1A AS A MARKER FOR CARDIAC ARRHYTHMIA - A method for assessing if a subject has or is at risk of developing cardiac arrhythmia is described. The method includes determining the activity of Rap1A protein in a bodily sample of the subject and comparing the activity of Rap1A protein from the bodily sample of the subject to at least one Rap1A control. A decreased level of Rap1A activity in the bodily sample of the subject as compared to the at least one Rap1A control indicates that the subject is at risk of developing or has cardiac arrhythmia. Methods for evaluating the efficacy of treatment of a subject having decreased Rap1A activity with an antiarrhythmic agent are also described.11-29-2012
20120114562METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS - A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.05-10-2012
20120014880METHOD FOR THE PREVENTION AND TREATMENT OF ESSENTIAL TREMOR BY REGULATING alpha1G T-TYPE CALCIUM CHANNEL OR BY T-TYPE CALCIUM CHANNEL BLOCKERS - The present invention relates to a method for the prevention and treatment of essential tremor by blocking α1G T-type calcium channel, a preventive and therapeutic agent for essential tremor containing the α1G T-type calcium channel blocker as an active ingredient, and a screening method of a preventive and therapeutic agent for essential tremor by investigating α1G T-type calcium channel blocking activity. More precisely, the present invention relates to a method for the prevention and treatment of essential tremor by using α1G T-type calcium channel blocker, for which the inventors confirmed that the α1G T-type calcium channel knock out mice (α1G−/−) had resistance against essential tremor and when the T-type channel blocker was administered to the wild type mice (α1G+/+), they gained resistance against essential tremor.01-19-2012
20090220426Biodegradable Inverted-Opal Structure, Method for Manufacturing and Using the Same, and Medical Implant Comprising the Biodegradable Inverted-Opal Structure - (Problems) The object of the present invention is to provide an inverted-opal structure which is excellent in biodegradability, biocompatibility, and pH responsiveness, has specific light reflection property due to three-dimensionally-ordered-pores formed therein, is capable of releasing a drug autonomously and intermittently by responding rapidly to pH change, and is capable of measuring the drug-release associated with its biodegradation by an optical means rapidly in a simple and easy way; a method for manufacturing the inverted-opal structure; a medical implant comprising the inverted-opal structure; a method for enlarging the pore diameter; and a method for measuring the release-amount of a drug held in the inverted-opal structure.09-03-2009
20090208416MONOCLONAL ANTIBODIES AGAINST NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.08-20-2009
20120156138Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming - The present invention provides a variety of nucleic acid based therapeutics and methods of use thereof which are effective to beneficially reprogram diseased cells such that they exhibit more desirable phenotypes. Also provided are compositions and methods to reprogram normal cells for medical and commercial purposes.06-21-2012
20120156137COMPOSITION FOR TREATMENT OF ATOPIC DERMATITIS COMPRISING GLUCOSAMINE AND DERIVATIVES THEREOF AND A METHOD FOR TREATMENT OF ATOPIC DERMATITIS USING THEM - Disclosed herein is a novel use of glucosamine or a derivative thereof. A pharmaceutical composition for treating atopic dermatitis comprising glucosamine or a derivative thereof and a method of treating atopic dermatitis using the composition are disclosed. The pharmaceutical composition and the method realize the safe treatment of atopic dermatitis without the side effects associated with conventional anti-inflammatory drugs.06-21-2012
20120064008COMPOSITIONS FOR THE TREATMENT OF METASTATIC CANCER AND METHODS OF USE THEREOF - An in vivo assay for assessing the metastatic potential of cancer cells has been developed. This is a functional assay that also allows for screening of compounds that are selective for metastatic cancer. Metastatic cancer is established in animals by intravenous injection of metastatic cancer cells before treatments are tested. This assay has been used to identify benzimidazoles for the treatment of metastatic prostate cancers. The benzimidazole(s) can be formulated for enteral or parenteral administration. In one embodiment, the compositions are formulated for parenteral administration. Compositions containing a benzimidazole exhibit greater cytotoxicity against cell lines prone to metastasis than against cells lines that are less prone to metastasis in vitro. The benzimidazoles described herein were effective at treating metastatic prostate cancer in bone. Administration of benzimidazoles in metastatic prostate cancer mouse models showed a significant increase in the survival times of the animals, even against paclitaxel resistant cancer cell lines.03-15-2012
20120064007METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.03-15-2012
20120064006SYSTEMS AND METHODS FOR USING PHYSIOLOGICAL INFORMATION - Systems and methods using a database of physiological information for the design, development, testing and use of therapeutics. In one aspect, the physiological information can include at least one of: hemodynamic monitoring information, pulmonary arterial pressure, cardiac output, heart rate, respiratory rate, peripheral vascular resistance, total peripheral resistance or dicrotic notch information. Optionally, the cardiovascular physiology information can include ambulatory physiological information.03-15-2012
20090162286Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions - The present invention provides methods to decrease body weight and/or body fat in animals, e.g., in the treatment of overweight or obese patients (e.g., humans or companion animals), or as a means to produce leaner meat in food stock animals (e.g., cattle, chickens, pigs), methods to treat non-insulin dependent diabetes (NIDDM), metabolic syndrome, or glucose intolerance, in patients in need thereof by administering a PDE10 inhibitor (alone or in combination with another therapeutic agent), kits for the above-identified therapeutic uses, and methods of identifying PDE10 inhibitors for the above-described therapeutic uses.06-25-2009
20110085983Liquid Chromatography-Mass Spectrometry Methods For Multiplexed Detection and Quantitation of Free Amino Acids - The present invention provides liquid chromatography-mass spectrometry methods and kits for the specific, sensitive and rapid detection as well as quantitation of free amino acids in samples following High Pressure Liquid Chromatography (HPLC) separation.04-14-2011
20090004112METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES USING NMDA RECEPTOR GLYCINE SITE ANTAGONISTS - The disclosure provides methods for treating a neurodegenerative disease by administering a NMDA receptor glycine site antagonist. Compounds that can be used in the methods are also provided. Methods are also provided for determining whether a compound inhibits activity of a Parkinson's Disease-associated mutant of leucine-rich repeat kinase-2 (LRRK2). The methods include assessing accumulation of axonal spheroid inclusions, branching and length of neuronal processes, and neuronal cell death.01-01-2009
20110104066PROPHYLACTIC/THERAPEUTIC AGENTS FOR LIFESTYLE-RELATED DISEASES - Disclosed is a method for the screening of a compound having an activity to selectively modulate an androgen receptor. The method comprises the steps of: contacting a substance to be tested with a prostate cancer cell and measuring the level of expression of mRNA for a prostate-specific antigen or the level of production of the prostate-specific antigen in the prostate cancer cell; and contacting the substance with an adipocyte and measuring the level of expression of mRNA for uncoupling protein-1 or the level of production of uncoupling protein-1 in the adipocyte. Also disclosed is a selective androgen receptor modulator comprising a compound represented by any one formula selected from the structural formulae (I) to (III) as an active ingredient. Further disclosed is a composition for preventing or treating lifestyle-related diseases, which comprises the selective androgen receptor modulator.05-05-2011
20110104065GENETIC ALTERATION ASSOCIATED WITH PRE-MALIGNANT CANCER - Described herein are progenitor cancer cells and cell lines isolated from human breast ductal carcinoma in situ (DCIS) lesions and the uses of these cells or cell lines in drug design, drug screening, and monitoring in vivo therapy. The DCIS malignant precursor cells or cell lines are epithelial in origin, are positive for markers of autophagy, show at least one genetic difference from normal cells of said fragment, form 3-D tube-like structures or ball aggregates, or are inhibited in formation of 3-D structures and migration by treatment with chloroquine. In one embodiment, there is a loss of heterozygosity (LOH) that is narrowly confined to a region of chromosome 6p (6p21.1-6p12.3) that contains the SUPT3H gene.05-05-2011
20100290996METHODS AND COMPOSITIONS BASED ON CULTURING MICROORGANISMS IN LOW SEDIMENTAL FLUID SHEAR CONDITIONS - This invention is directed to applying a low sedimental fluid shear environment to manipulate microorganisms, and to microorganisms and compositions obtained based on such manipulation. Specifically, the present invention provides methods of modifying a molecular genetic or phenotypic characteristic (e.g., virulence, stress resistance or biofilm formation) of a microorganism by culturing in a low sedimental shear environment. One or more ion concentrations in the culture can be modulated in order to inhibit or amplify the extent of the modification. The present invention also provides microorganisms obtained from a low sedimental shear culture, which exhibit modified and desirable phenotypic characteristics, as well as therapeutic, vaccine and bioindustrial products prepared from such microorganisms. Further, the present invention provides methods for identifying molecules that modulate responses of a microorganism to a low sedimental shear environment and for determining the relevance of such molecules to pathogenenicity of the microorganism.11-18-2010
20090136427LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment - Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder.05-28-2009
20100092389DETECTION OF ATHEROSCLEROSIS USING INDOCYANINE GREEN - Exemplary embodiments of apparatus and method can be provided for imaging a portion of an anatomical structure. According to an exemplary embodiment of the present invention, an indocyanine green (ICG) agent can be provided to at least one portion of an anatomical structure, and it can be determined whether at least one plaque structure associated with the at least one portion includes at least one of an angiogenesis or an inflammation based on the interaction between the ICG agent and the at least one portion.04-15-2010
20120164078METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.06-28-2012
20120164077PREDICTIVE ASSAYS FOR CELL TRANSPLANTATION EFFICACY AND METHODS OF USING HUMAN NEUROPOTENTIATING CELLS - The present invention provides a method of treating mammalian brain injuries, which entails administering human neuropotentiating cells to a brain of a mammal in need thereof in order to enhance dendritic and axonal plasticity, and axonal transport.06-28-2012
20120164076METHODS OF TREATMENT USING THYMUS-DERIVED COMPOSITIONS - Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to cancer. In preferred synergistic aspects, the inventive compositions (Thyex-1-6A and -6B) are administered in combination with a macrophage stimulating agent (e.g., beta glucan) for cancer treatment. Certain aspects relate to treating cancer, comprising: administering of a therapeutically effective amount of a thymus extract composition (Thyex-1-6A and -6B) in combination with administration of an extract of 06-28-2012
20120164074METHODS OF DIAGNOSING, PREVENTING AND TREATING CANCER METASTASIS - The invention relates to methods and compositions for inhibiting metastasis, such as by inhibiting FOXC2 expression or activity. The invention further relates to methods of prognosticating, diagnosing, and assisting in the diagnosis of metastasis in an individual, or of determining the metastatic potential of a tumor. The invention further relates to methods of identifying agents which inhibit metastasis.06-28-2012
20100247443EFFECTIVENESS EVALUATING METHOD, EFFECTIVENESS EVALUATING DEVICE, AND EFFECTIVENESS EVALUATING PROGRAM FOR EXTERNAL PREPARATION FOR SKIN - An effectiveness evaluating method evaluates effectiveness of an external preparation for skin for protection against ultraviolet irradiation after the external preparation is applied to the skin. The method includes a measurement step of measuring an amount of urocanic acid in a horny cell layer by Raman spectroscopy both before and after the application of the external preparation and both before and after exposure to ultraviolet irradiation, an index derivation step of computing at least one index for evaluating the effectiveness of the external preparation based on results of the measurement obtained in the measurement step, and an evaluation step of evaluating the effectiveness of the external preparation by using the index obtained in the index derivation step.09-30-2010
20100247442Macaca fascicularis ST2L - Isolated polynucleotides encoding 09-30-2010
20100247440MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT - Methods of Mycobacterial immunotherapy for the treatment of cancer are described. In certain cases, these methods concern administration of attenuated Mycobacteria by intradermal injection into non tumor tissues. Methods of the invention, provide safe and effective treatments for malignant tumors and the compositions for use in such treatments. Methods for determine the effectiveness of such immunotherapies are also described.09-30-2010
20100247441SITE LOCALIZATION AND METHODS FOR MONITORING TREATMENT OF DISTURBED BLOOD VESSELS - Methods for identifying defects in blood vessels and treating such defects are provided. The methods comprise administering to a patient a composition comprising a labeled delivery ligand capable of preferentially accumulating at or near blood vessels defects. In some embodiments, the delivery ligand may carry one or more active agents to the defect.09-30-2010
20100209350Biomarkers for Adipose Tissue Activity - The invention provides compositions and methods for determining a subject's adipose tissue activity. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, adiponectin, resistin, PAI-1, optionally leptin and optionally visfatin. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in identifying adipose tissue activity, which is associated with various disease states including chronic or systemic inflammation, atherosclerosis and other cardiovascular risks and complications. The invention also provides methods of treating a subject and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein.08-19-2010
20100209351Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level - Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.08-19-2010
20100209349Phage Therapy Against Pseudomonas Aeruginosa - This invention relates to a bacteriophage MPK6 (deposit number: KCCM 11044P) having a lytic activity to 08-19-2010
20110182817ANTIBODY AGAINST CALCIFIED GLOBULE AND USE OF THE SAME - The present inventors carried out immunization using renal/urinary calculus-derived calcified globules or carotid artery-derived arteriosclerotic plaques, and then obtained antibodies specific to calcified globules (NLO) via screening with NLO. The present inventors demonstrated that the antibodies reacted specifically to arteriosclerotic lesions (calcified lesions) and visualized arteriosclerotic plaques (in particular, calcified lesions) by using fluorescently labeled antibodies. Accordingly, the present inventors completed the present invention.07-28-2011
20110182820METHODS FOR THE PREDICTION OF SHORT-TERM AND LONG-TERM COGNITIVE DECLINE IN ALZHEIMER'S DISEASE PATIENTS USING CSF BIOMARKERS - The present invention provides a method for predicting the short-term and long-term cognitive decline in Alzheimer's disease patients and uses thereof in predicting efficacy of an AD therapeutic. The method uses baseline levels of CSF biomarkers to predict decreases over time in CAMCOG and MMSE scores.07-28-2011
20110182818METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF NEUROLOGICAL AND MENTAL HEALTH DISORDERS - A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.07-28-2011
20110182816ANTIBODY AGAINST OXIDIZED LDL/ 2GPI COMPLEX AND USE OF THE SAME - From antibodies that can be used to immunostain atherosclerotic tissue sections, the present inventors selected antibodies applicable to in vivo imaging, and analyzed their specificities. The result showed that fluorescently labeled anti-oxidized LDL/β07-28-2011
20120134928MODULATION OF TERMINASE ACTIVITY AT TELOMERES AND DNA DOUBLE-STRAND BREAKS - The present invention is directed to compositions and methods concerning terminase proteins. In particular, the present invention is directed to terminase proteins and their function in processing telomeres and double-strand breaks.05-31-2012
20120134929TREATMENT OF MACROPHAGE-RELATED DISORDERS - The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.05-31-2012
20120219505PEPTIDE REAGENTS AND METHODS FOR DETECTION OF COLON DYSPLASIA - The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.08-30-2012
20100329987Uses of Sperm Membrane Protein OBF - The present invention yielded unique monoclonal antibodies that reacted specifically only to sperms after acrosome reaction, and the antigens (OBFs) recognized by the antibodies were identified. The antibodies were found to inhibit fusion between mouse sperms and eggs. Furthermore, OBF gene-knockout mice were created and analyzed to clarify the in vivo functions of OBF. As a result, male OBF gene-knockout mice were shown to be infertile, and their sperms were shown to be able to bind to eggs, but had no fusion ability.12-30-2010
20100172841VIABLE NEAR-INFRARED FLUOROCHROME LABELED CELLS AND METHODS OF MAKING AND USING THE SAME - The invention provides viable near-infrared fluorochrome labeled cells and in vivo imaging methods for tracking, locating or determining the quantity of the viable cells once they have been administered to a subject.07-08-2010
20120219506Catenae: Serosal Cancer Stem Cells - The present invention relates to a clonally pure population of serosal cancer stem cells (CSCs) as well as methods of producing and culturing the CSCs and uses thereof. The CSCs form catenae (free floating chains of cells) which have a glycocalyx coat of hyaluronan and proteoglycans. This discovery has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of glycocalyx formation, including combination therapies using chemotherapeutics in conjunction with glycocalyx inhibitors. The invention also provides drug screening assays for identifying compounds effective against these CSCs as well as other serosal cancer cells. Methods to use catena gene signatures, protein and surface antigens are provided for monitoring patient samples for the presence of serosal cancer stem cells.08-30-2012
20090081128Model of Alzheimer's Disease - A modified non-human warm-blooded vertebrate animal in which a biologically active human APP polypeptide is expressed, and in which function of its inducible Nitric Oxide Synthase (iNOS) protein is reduced as compared to a non-modified animal, methods of making the animal, and methods of testing a candidate composition for activity in the treatment of Alzheimer's Disease using the animal.03-26-2009
20120213706RECONSTITUTED TUMOR MICROENVIRONMENT FOR ANTICANCER DRUG DEVELOPMENT - Extracellular matrix bioscaffolds capable of supporting the formation and growth of tumors from tumor cells introduced thereto containing tumor associated macrophages and carcinoma-associated fibroblast-like cells cultured under conditions effective to provide a cellular matrix capable of supporting the formation and growth of tumors from tumor cells introduced to the matrix. Bioscaffold kits and methods for using the bioscaffolds for testing, identifying and development of known or novel anti-cancer therapeutics are also disclosed.08-23-2012
20120213708HYDROGEL ENCAPSULATED CELLS AND ANTI-INFLAMMATORY DRUGS - A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.08-23-2012
20120213707Riboflavin Based Aerosol and Use as Placebo in Trials - A method for evaluating an aerosolized test compound includes administering a test compound to a first population of individuals, via inhalation of an aerosol; administering a placebo comprising riboflavin 5′-phosphate to a second population of individuals, via inhalation of an aerosol; and comparing a biological marker for the individuals in the two populations. An aerosol comprising riboflavin 5′-phosphate (also known as flavin mononucleotide) may be used either as a placebo in clinical trials, or therapeutically.08-23-2012
20120076732PHOSPHODIESTERASE INHIBITORS AND USES THEREOF - The invention provides for compounds that are phosphodiesterase inhibitors. The invention further provides for a method for screening compounds that bind to and modulate a phosphosdiesterase protein. The invention also provides methods for treating conditions associated with accumulated amyloid-beta peptide deposit accumulations by administering a phosphodiesterase-binding compound to a subject.03-29-2012
20120076731Lymphedema associated genes and model - The present invention identifies genes whose gene products are differentially expressed in lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lymphedema. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing lymphedema.03-29-2012
20080213183Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin - The use of the maximum tolerated dose (MTD) of individual drugs to determine appropriate administration ratios of drugs for combination therapy, wherein the ratios of drugs are fixed based on the same percentage of the MTD for each drug. Furthermore, antineoplastic compositions comprising liposomal encapsulated gemcitabine alone or in combination with free or liposomal encapsulated antineoplastic agents, such as idarubicin, irinotecan, etopside, cisplatin, cyclophosphamide, doxorubicin, or vincristine are diclosed.09-04-2008
20080213182Methods and Compositions for Treatment of Diseases Associated with Aberrant Microsatellite Expansion - The present invention provides methods and compositions for the treatment of diseases associated with aberrant microsatellite expansions. Methods of the present invention comprise the use of recombinant adeno-associated virus vectors containing a transgene encoding at least one muscleblind protein. The present invention also provides an animal model for a disease associated with aberrant microsatellite expansion.09-04-2008
20120177577Genetically Modified Rat Models for Severe Combined Immunodeficiency (SCID) - This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are dencient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.07-12-2012
20100272647RECEPTOR - We disclose BACH G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof Nucleic acids capable of encoding BACH polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No.2 or SEQ ID NO: 4 or a mouse BACH genomic sequence (SEQ ID NO: 10).10-28-2010
20100272646METHOD FOR INDUCING LYMPHOID TISSUE AND MODULATING INTESTINAL HOMEOSTASIS - Methods and products for modulating the lymphoid system, especially intestinal homeostasis between intestinal lymphoid tissues and gut flora using ligands for NOD1 and/or CCR6.10-28-2010
20090246139Efficient methods to isolate effectors of proteins involved in olfactory or chemosensory pathways and efficient methods to use these effectors to alter organism olfaction, chemosensation, or behavior - This invention provides methods and compositions for identifying effectors, binding partners, or other molecules that interact with the proteins involved in the chemosensory pathway; examples of proteins involved in the olfactory pathway include odorant binding proteins (OBPs), sensory appendage proteins (SAPs), orthologs of the 10-01-2009
20100047176Method and Kit for Testing Stress Effects in Living Organisms - The present invention concerns a method of testing whether a living organism has been exposed to stress, such as pesticide exposure, e.g., whether weed crops have been exposed to herbicide. Based on non-separated compounds obtained from an organism, e.g., an extract from a plant, a color development is generated. The color or shade developed is dependent on the compounds of the organism. By comparing the color or shade of the extract obtained from an organism with a standard color scale developed with respect to the same organism, it is possible to determine the final effect of the stress upon the growth of the plant. The invention also concerns a method of providing a standard color scale for material from a living organism that has been exposed to stress, e.g., a pesticide. As assay kit for the determination of the final effect of the stress upon the growth of the plant is also described. The present invention may be used by farmers or advisors to predict the final effect of herbicide treatment of plants before visual signs appear on the plants.02-25-2010
20120225018HOMEOPATHIC THERAPEUTIC METHOD AND COMPOSITIONS - The present invention relates to compositions including a homeopathic aqueous substance active (HASA) and at least one hydrophilic gelling agent, the HASA comprises a homeopathic compound at a potency of 30 C or higher and an uninhibited aqueous composition. The present invention also relates to methods of preparing a hydrophilic HASA-gel matrix. The method includes combining a homeopathic compound and an uninhibited aqueous composition to produce a HASA; combining the HASA with at least one hydrophilic gelling agent; and thereafter, forming the hydrophilic HASA-gel matrix by use of at least one of a thickening agent, a crosslinking agent, or a polymerization agent.09-06-2012
20120225019Dual Fluorescence Assay For Determining Viability Of Parasitic Or Non-Parasitic Worms - A two colour fluorescent assay and a kit are described that permit the determination of live and dead parasitic or non-parasitic worms, for example helminths. The assay permits screening for the effect of one or more agents or an event on the viability of a parasitic or non-parasitic worm. In one example, the assay comprises (a) providing a sample comprising one or more parasitic or non-parasitic worms; (b) contacting the parasitic or non-parasitic worms with a concentration of fluorescein diacetate sufficient to yield detectable green fluorescence in any live parasitic or non-parasitic worms present in the sample and a concentration of propidium iodide sufficient to yield detectable red fluorescence in any dead parasitic or non-parasitic worms present in the sample; and (c) detecting the red and green fluorescence of the parasitic or non-parasitic worms. The assay further comprises contacting the parasitic or non-parasitic worms with one or more test agents, or subjecting the parasitic or non-parasitic worms to an event. The assay allows for a rapid and objective score of parasitic or non-parasitic worm death and survival and enables the performance of high- throughput screens for the identification of potential agents against diseases such as schistosomiasis. Also described are methods and kits for discriminatory analysis of parasitic or non-parasitic worm phenotype and/or metabolics using FTIR analysis.09-06-2012
20120082623SHH Regulation and Methods Thereof - The invention provides for methods of upregulating endogenous GDNF by inhibiting Shh signaling. The invention further provides a method for increasing the production of cholinergic neurons and dopamine neurons by subventricular zone (SVZ) neurogenesis in a subject. The invention further provides methods for treating a neurodegenerative disorder in a subject.04-05-2012
20120082622Macaca fascicularis CCL17 - Isolated polynucleotides encoding 04-05-2012
20090016963Genes involved in neurodegenerative conditions - The invention discloses suitable gene and polypeptide targets for the development of new therapeutics to treat, prevent or ameliorate neurodegenerative conditions. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds with therapeutic usefulness to treat neurodegenerative conditions.01-15-2009
20120230917COMPOSITIONS THAT INCLUDE A HYDROPHOBIC COMPOUND AND A POLYAMINO ACID CONJUGATE - Various compositions that include a hydrophobic compound and a polyamino acid conjugate are prepared. The compositions described herein are useful for a variety of drug, biomolecule, and imaging agent delivery applications.09-13-2012
20120230916Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof - A method of providing a patient with controlled release of ketone-containing opioid using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing the ketone-containing opioid is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of the ketone-containing opioid from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.09-13-2012
20110123455RATIONAL DESIGN OF REGENERATIVE MEDICINE PRODUCTS - The present invention concerns a non-biased, combinatorial approach to the identification of components that modulate a regenerative response in a target tissue, thereby restoring or partially restoring homeostasis to the target tissue. The methods of the present invention are based on in vivo testing, with or without prior in vitro predictive functional testing or combinatorial testing.05-26-2011
20110123454Method for modulating appetite - The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1-modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject.05-26-2011
20110027187THERAPEUTIC OR PROPHYLACTIC AGENT, DETECTION METHOD AND DETECTION AGENT FOR METABOLIC SYNDROME, AND METHOD FOR SCREENING OF CANDIDATE COMPOUND FOR THERAPEUTIC AGENT FOR METABOLIC SYNDROME - The object is to provide: a therapeutic or prophylactic agent for metabolic syndrome, which has improved stability in a living body; and others. The therapeutic or prophylactic agent for metabolic syndrome comprises, as an active ingredient, DNA that encodes receptor activity-modifying protein (RAMP) 2 and is selected from the items (a) to (d) below or a polypeptide encoded by the DNA: (a) DNA which has the nucleotide sequence depicted in SEQ ID NO:1; (b) DNA which has a nucleotide sequence capable of hybridizing with the nucleotide sequence depicted in SEQ ID NO:1 under stringent conditions; (c) DNA which has a nucleotide sequence encoding an amino acid sequence having the substitution, deletion and/or addition of one or more amino acid residues in the amino acid sequence depicted in SEQ ID NO:2; and (d) DNA which has a nucleotide sequence having a 90% or more homology with the nucleotide sequence depicted in SEQ ID NO:1.02-03-2011
20110038800METHOD FOR THE TREATMENT OR PROPHYLAXIS OF LYMPHAGIOLEIOMYMATOSIS (LAM) AND ANIMAL MODEL FOR USE IN LAM RESEARCH - Treatment of lymphangioleiomyomatosis with the MEK1/2 inhibitor CI-1040 delayed the development of primary tumors and blocked the estrogen-induced lung metastases in treated animals. Such treatment also reduced the number of circulating ELT3 cells and decreased their lung colonization after intravenous injection.02-17-2011
20110038799COMPOSITION FOR TREATMENT AND IMPROVEMENT OF DIABETES COMPRISING CAVEOLIN AS ACTIVE INGREDIENT AND A METHOD FOR TREATMENT OF DIABETES USING IT - The present invention relates to a composition for the treatment and improvement of diabetes comprising caveolin as an active ingredient and a method for treating diabetes using the same, more precisely a composition comprising caveolin-1 as an active ingredient for the treatment and improvement of type II diabetes which is age-dependent but not showing obesity symptom and a method for treating diabetes using the same. The treatment method and composition of the present invention is very effective in improving and treating diabetes by regulating insulin sensitivity by increasing caveolin level in muscle tissues of type II diabetes patient which is age-dependent but not showing obesity symptom.02-17-2011
20120269732METHODS OF CONTROLLING TUMORIGENESIS AND DIAGNOSING THE RISK THEREOF - The present invention relates to methods of controlling tumorigenesis, including preventing, inhibiting, arresting or reversing tumorigenesis. The present invention also provides methods of treatment, prevention and diagnosis of neoblastoma, including cancer, such as metastatic cancer. In one method one or more cells having a predisposition to turn tumorigenic are identifyied. In the one or more cells an altered amount, an altered subcellular localisation or an altered activity of a Rab binding protein is detected. In a method of diagnosing the risk of developing a neoplasmt at least one of the expression level, the activity level and the subcellular localisation of a Rab binding protein is determined. In an in-vitro method of identifying a compound capable of forming a complex with a Rab binding protein the components that form the respective complex are contacted with each other. In a method of determining whether a neoplasm is sensitive to an alteration of intracellular calcium levels, at least one of the expression and the activity of a Rab binding protein is determined. An altered expression or an altered activity of the Rab binding protein is an indication that the neoplasm is sensitive to an alteration of intracellular calcium levels.10-25-2012
20120269733Model Systems and Treatment Regimes for Treatment of Neurological Disease - The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents.10-25-2012
20110217240IMAGING NEUROLEPTIC COMPOUNDS - A method for identifying typical and atypical antipsychotics based on their ability to reduce neuronal/glial activity in specific brain regions upon dopaminergic neurotransmission is disclosed.09-08-2011
20090257956Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation - A method for a same visit treatment for erectile dysfunction and premature ejaculation. The method includes: performing a diagnostic on the patient using physical conditions of the patient; determining a diagnostic group of the patient, wherein each diagnostic group has corresponding conditions to the physical conditions of the patient; identifying an age group of the patient; selecting a first test dose of a pharmaceutical composition, which corresponds to the age group and the diagnostic group of the patient, wherein the pharmaceutical composition is a solution with PGE1, papaverine, phentolamine, and atropine; administrating the first test dose to the patient; observing the physical conditions of the patient after the administration of the first test dose; determining a result group of the patient after observing the physical conditions of the patient; and prescribing a same visit dosage for the patient based on the result group.10-15-2009
20110236317TETRAHYDROTRIAZINE COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH AMPK ACITIVITY - The invention relates to compounds of formula (I) wherein the radicals R09-29-2011
20100233088METHOD OF IDENTIFYING STRATEGIES FOR TREATMENT OR PREVENTION OF VENTRICULAR FIBRILATION AND VENTRICULAR TACHYCARDIA - The present invention relates to evaluating the effect of physiological conditions on the occurrence of ventricular fibrillation, identifying strategies for treatment or prevention of ventricular fibrillation or ventricular tachycardia, and evaluating a subject for induction of ventricular fibrillation from a condition of ventricular tachycardia.09-16-2010
20100233087CYP1B1 NUCLEIC ACIDS AND METHODS OF USE - The present invention provides nucleic acids containing transcriptional units that encode CYP1B1 polypeptides or portions thereof, wherein the transcriptional units lack sequences found in the untranslated region (UTR) of naturally occurring forms of the CYP1B1 transcript. The nucleic acids of the invention lack translational repressor elements and thus provide for a system of enhanced translation of the CYP1B1 polypeptide or portions thereof. Also disclosed are methods of administering nucleic acids to a mammal and use in the treatment of proliferative disorders or cancer.09-16-2010
20120087866NEEDLE ARRAY ASSEMBLY AND METHOD FOR DELIVERING THERAPEUTIC AGENTS - A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.04-12-2012
20120087865TREATMENT OF ISCHEMIA - A system, including methods and compositions, for treatment of ischemia.04-12-2012
20120087864METHOD FOR DIAGNOSING AND/OR EVALUATING RETINAL DISEASE - The present application provides a method for diagnosing and/or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and/or evaluating circulatory parameters, retinal function, retina morphology and/or visual relating quality of life (QOL).04-12-2012
20120282184TREATMENT OF OBESITY - A method for the prevention or treatment of a condition selected from type 2 diabetes, obesity and metabolic syndrome comprising activating a GITRL pathway. Methods for screening for substances to treat these conditions, diagnosing or predicting these conditions and selecting and monitoring therapies.11-08-2012
20120282183PROGNOSTIC,. SCREENING AND TREATMENT METHODS AND AGENTS FOR TREATMENT OF METASTASIS AND INFLAMMATION USING 5T4 ONCOFOETAL GLYCOPROTEIN - Methods and agents are disclosed based on the finding that 5T4 interacts with CXCR4 in the cell membrane to form a complex, and that the 5T4 transmembrane region is involved in the promotion of CXCR4 membrane expression and chemotactic response.11-08-2012
20120328526Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof - The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD12-27-2012
20120328527METHODS OF ENHANCING FUNCTIONING OF THE LARGE INTESTINE - The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.12-27-2012
20120328525NANOPARTICLE COMPOSITIONS AND COMPONENTS THEREOF - The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis, among others. Methods generally involve administering provided compositions to the skin.12-27-2012
20120100076METHODS OF MODULATING COLD SENSORY PERCEPTION - The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction.04-26-2012
20120288447PEPTIDE WHICH PASSES THROUGH BLOOD-BRAIN BARRIER AND TARGETS APOPTOSIS OF NEURODEGENERATIVE BRAIN DISEASE SITE AND USES THEREOF - The present invention relates to a peptide that passes through a blood-brain barrier and targets apoptosis of neurodegenerative brain disease-affected sites and uses thereof. More particularly, the present invention relates to a composition for delivering drugs to brain tissues, a composition for detecting apoptotic cells of neurodegenerative brain disease-affected sites, and a composition for imaging the neurodegenerative brain disease-affected sites which comprises a peptide having an amino acid sequence represented by SEQ ID: No. 1 respectively, and a composition for prevention, treatment, or theranosis of neurodegenerative brain diseases comprising said peptide. The peptide of the present invention can be used for detecting apoptosis in neurodegenerative brain diseases and further detecting apoptotic cells (especially apoptotic neuronal cells) in neurodegenerative brain disease-affected sites and imaging, targeted drug delivery, theranosis.11-15-2012
20100202972USE OF GENE VARIANTS OF THE HUMAN MEIS1, BTBD9, MAP2K5, LBXCOR1, PTPRD OR A2BP1 GENE FOR DIAGNOSTIC AND THERAPEUTIC APPROACHES TO RESTLESS LEGS SYNDROME (RLS) - The present invention relates to an oligo- or polynucleotide which can be used in the diagnosis and therapy of restless legs syndrome (RLS). Furthermore, the invention relates to methods of diagnosing a predisposition for or RLS and a method for selecting a therapy to prevent and treat RLS. Moreover, a method for determining the dose of a drug used for treating a patient suffering from RLS and a method to test the efficacy of a drug used for treating RLS in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias as well as the use of a drug effective in treating RLS for testing the efficacy of said drug in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias. The invention also envisages methods of identifying an inhibitor, pro-drug or drug capable of modulating the activity of a peptide or protein of the invention, a diagnostic kit for detection of a single nucleotide polymorphism and gene therapies on the basis of gene variants detected with the present invention.08-12-2010
20090214431IDENTIFICATION OF ERGOTHIONEINE TRANSPORTER AND THERAPEUTIC USES THEREOF - The transporter that translocates ergothioneine has been identified. Described are methods for identifying and obtaining compounds capable of modulating ergothioneine transport as well as the use of such compounds for the treatment of diseases ergothioneine may be involved in such as autoimmune diseases, in particular rheumatoid arthritis, as well as other diseases arising from cell damage caused by radiation, radicals and relative oxidant species. Furthermore, diagnostic means and methods for determining the presence or susceptibility to such a disease are provided.08-27-2009
20100166660METHODS OF MODELING MIGRAINE PAIN AND IDENTIFYING CANDIDATE COMPOUNDS FOR THE TREATMENT OF MIGRAINE - The present invention features animal models of migraine pain that can be used in a variety of ways, e.g., to identify compounds that reduce migraine pain or other migraine symptoms, to investigate behavioral changes correlated with the development and maintenance of a migraine-like state, and to better understand the mechanisms that underlie migraine pain.07-01-2010
20100143257Prevention of Cancers by Immunization - In healthy subjects, especially the ones with increased risk for developing cancer due to genetic predisposition or other risk factors, cancer can be prevented by immunization with a cancer vaccine. Oncoantigens present in the vaccine preferably are incubated with IFN-γ, IL-2 or both. To prevent cancer recurrence, cancer patients in remission are given a prolonged course of immunizations with a vaccine that includes, for example, oncoantigens in combination with immune competent cells (e.g., bone marrow and T lymphocytes). The bone marrow and T lymphocytes are optionally treated with IFN-γ, IL-2 or both.06-10-2010
20130017151SUBSETS OF ANTIGEN-PRESENTING CELLS (APCs) IN THE HUMAN VAGINA AND THEIR DISTINCT FUNCTIONS - Compositions and methods for generating dendritic cell (DC)-targeting vaccines against vaginal infections, including but not limited to sexually transmitted diseases, are disclosed herein. The present invention reports the isolation of at least four major subsets of myeloid-originated antigen-presenting cells (APCs) that possess distinct phenotypes and functions in directing immune responses, namely, Langerhans cells (LCs: E-cadherin01-17-2013
20110158912METHOD AND DEVICE FOR DETERMINING THE SEVERITY OF A PAIN DISORDER - A method for determining the severity of a pain disorder in a subject, comprising the steps of: (i) topically applying an effective amount of menthol or a functional equivalent thereof to the subject's painful area and other locations; and (ii) measuring the response of the subject06-30-2011
20130022547ATTENUATED MYCOPLASMA GALLISEPTICUM STRAINS - The present invention provides live, attenuated 01-24-2013
20090202440MODEL ANIMAL OF DENDRITIC CELL IMMUNORECEPTOR GENE KNOCKOUT DISEASE - It is intended to disclose the function of dendritic cell immunoreceptor (DCIR) and clarify its role in the onset of autoimmune arthritis. It is also intended to provide a method of screening a substance which is useful in treating/preventing an autoimmune disease or osteoporosis. A nonhuman disease model animal characterized by having a partial or entire deficiency of a gene encoding the DCIR protein on the chromosome; a method of screening a substance which is useful in treating/preventing a DCIR-related disease, for example, an autoimmune disease such as arthropathy by using the nonhuman disease model animal as described above; and a remedy/preventive therefor.08-13-2009
20080247953METHODS AND COMPOSITIONS FOR AFFECTING SUBSTRATE DOCKING OF KINASES IN MODULATING CELLULAR ACTIVITIES - The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. This includes primarily diseases or conditions associated with immune responses and can include treatment for cancers as well as various immune disorders. The invention reports a novel substrate SH2 domain docking mechanism apart from the kinase active site that is required for appropriate tyrosine phosphorylation by these tyrosine kinases.10-09-2008
20130171072DYES AND METHODS OF SELECTING DYES FOR USE IN PERSONAL CARE PRODUCTS - Dyes and methods of selecting dyes for use in personal care products are provided. An exemplary method includes selecting a dye concentration of a dye that is brightly or intensely colored, determining a dye concentration of the dye that does not change the color of skin or minimally changes the color of skin, and determining a dye concentration of the dye that does not transfer color or minimally transfers color. An exemplary dye includes, by weight percent of the personal care product in which such dye is provided, approximately 0.001500% Red 33 dye and 0.003750% Orange 4 dye.07-04-2013
20130171073TREATMENT OF PITUITARY CORTICOTROPH TUMORS USING R-ROSCOVITINE - The present invention describes methods of treating a pituitary tumor, methods of suppressing ACTH and/or corticosterone levels in an ACTH-secreting pituitary adenoma, methods of inhibiting the growth of an ACTH-secreting pituitary adenoma and methods of treating Cushing's disease. These methods can include providing a composition comprising R-roscovitin or a salt thereof and administering the composition to a mammalian subject in need thereof.07-04-2013
20080241070FENOFIBRATE DOSAGE FORMS - Disclosed are redispersible fibrate, such as fenofibrate, dosage forms. Also disclosed are in vitro methods for evaluating the in vivo effectiveness of fibrate, such as fenofibrate, dosage forms. The methods utilize media representative of in vivo human physiological conditions.10-02-2008
20080241069Methods and compositions for treating IgE-mediated diseases - This invention provides recombinant peptides comprising a fragment of an IgE constant region, nucleotide molecules encoding same, recombinant vaccine vectors comprising same, and methods for inducing immune response and treating allergy, asthma and IgE mediated disease comprising same.10-02-2008
20080241067Methods of Modulating Metastasis and Skeletal Related Events Resulting From Metastases - The invention provides, inter alia, models of bone metastasis, methods for identifying agents that modulate skeletal related events and metastasis, methods for modulating skeletal related events and metastases, and methods for detecting skeletal related events and metastases. The methods and models generally comprise co-culturing cancer cells and host cells and comparing biological markers from such co-cultured cells to control cells.10-02-2008
20080226559Benztropine Compounds and Uses Thereof - Disclosed are benztropine analogs having the formula (I) in which Ar is a C09-18-2008
20120251457METHODS AND COMPOSITIONS FOR MODULATING ADIPOCYTE FUNCTION - Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7.10-04-2012
20120251456Method for Assessing Skin Condition - A method for evaluating the efficacy of a skin-cleansing composition comprises measuring an ATP level on a skin site after cleansing. A method for evaluating the condition of living skin comprises measuring an ATP level on a skin site. The ATP level may be monitored over time to determine a rate of change in the ATP level on the skin site.10-04-2012
20120251455Hair Growth-Inhibiting Agent - A hair removing agent or a hair growth inhibiting agent is provided by determining an endogenous factor having a hair growth inhibitory activity, screening for substances having an activity similar to that of the endogenous factor or substances enhancing the activity or expression of the endogenous factor, and utilizing the physiological activities of such substances. It has been found that FGF18 inhibits hair growth. A method of screening for FGF18-like active substances, substances that promote the activity of FGF18 or substances that promote the expression of FGF18 to thereby obtain candidates for the hair growth inhibiting agent or hair removing agent is disclosed. Also disclosed is a hair growth inhibiting agent or a hair removing agent comprising, as an active ingredient, FGF18 and/or an FGF18 partial peptide, or an FGF18-like active substance and/or a substance that promotes the activity or expression of FGF18 (e.g., Digenea simplex extract).10-04-2012
20130095041Skin Profiling and Its Use in Testing Cosmetics - A method of profiling skin comprises comparing the rugosity and/or the length of rete ridges beneath the skin relative to a length of skin and optionally also the relative thicknesses (or volumes) of the dermis and the epidermis. The method allows for determination of the ability of a cosmetic formulation to hydrate or “plump” skin.04-18-2013
20130115171NAV1.7-RELATED ASSAYS - A viable global Na05-09-2013
20130101515METHOD OF SELECTING ANTIOXIDANTS FOR USE IN TOPICALLY APPLIED COMPOSITIONS - The invention provides antioxidant-containing compositions and methods for confirming antioxidant activity of a composition formulated for topical application to skin. The invention also provides methods for testing a composition for the ability to inhibit both ultraviolet radiation-induced lipid peroxidation on skin and ultraviolet radiation-induced reactive oxygen species formation in the stratum corneum, as well as compositions and methods for treating and preventing photodamage to skin.04-25-2013
20090220428Insect Repellent and Process for Identifying Other Insect Repellent Molecules - This invention is based on the identification of the role played by the receptor mX on certain insects through the behavior evinced in the taste sensory reactions of these insects. The invention addresses the use of the modulators on the mX receptor, such as L-canavanine and/or a mix of arginine and calcium and/or N-methyl-L-arginine (NMA) which are used to prepare a compound with repellent or attractive qualities with regard to certain insects. The invention also concerns the use of an mX insect receptor as a target for the identification of repellent substances regarding at least some insects.09-03-2009
20130136695METHODS AND COMPOSITIONS INCLUDING SPORE-FORMING BACTERIA FOR INCREASING THE HEALTH OF ANIMALS - Methods, compositions and bacterial isolates for improving the gastrointestinal health of animals and in particular of poultry are provided herein. The methods include administering an endospore-forming bacteria to an animal. The bacteria are selected for the ability to reduce the growth and presence of bacterial pathogens, such as 05-30-2013
20110236319METHOD OF EVALUATING PLANT PROTECTION - A method is provided for evaluating a protected plant having a protection mechanism. A population of immature insects (i.e., larvae or nymphs) belonging to an insect species having a plurality of instars is first exposed to the protected plant such that the protected plant is at least contacted thereby. The insect exposure extends for a selected time period corresponding to a sublethal exposure of the insect population to the protected plant. The exposure of the insect population to the protected plant is then halted following the selected time period and insects collected. A physical characteristic of at least some collected insects is measured. The measured physical characteristics are then statistically analyzed so as to determine an efficacy of the protection mechanism of the protected plant with respect to the insect population. Associated methods are also provided.09-29-2011
20110236316PEPTIDE TARGETING IMAGING AGENTS AND METHODS OF USE THEREOF - Described herein are peptide targeting imaging agents. The peptides are covalently attached to the imaging agent and have a specific peptide sequence that enables the imaging agent to accumulate specifically in tumor tissues. Additionally, the imaging agents are readily excreted by the subject within a short period of time after administration to the subject. Methods for using the imaging agents are also described herein.09-29-2011
20110256063MEX3C REGULATION AND TARGET TO CONTROL OBESITY AND DIABETES - MEX3C deficiency impairs the development of white and brown adipose tissue. Hence the present invention provides, among other things, a method of screening a candidate compound for activity in inhibiting fat deposition in a subject in need thereof and/or treating a condition in a subject in need thereof, comprising: (a) contacting a candidate compound to a cell that expresses MEX3C protein; and then (b) detecting a quantity of expression of the MEX3C protein in the cell; a depression in the expression of MEX3C protein when the candidate compound is contacted thereto as compared to that expressed when the candidate compound is not contacted thereto indicating the compound is active in inhibiting fat deposition and/or treating a condition in a subject in need thereof. Methods of treatment and screening subjects are also described.10-20-2011
20120276013GENETICALLY DETERMINED MOUSE MODEL OF RESISTANCE TO TRANSPLANTABLE CANCERS - We have established and studied a colony of mice with a unique trait of host resistance to both ascites and solid cancers induced by transplantable cells. One dramatic manifestation of this trait is age-dependent spontaneous regression of advanced cancers. This powerful resistance segregates as a single-locus dominant trait, is independent of tumor burden and is effective against cell lines from multiple types of cancer. During spontaneous regression or immediately following exposure, cancer cells provoke a massive infiltration of host leukocytes which form aggregates and rosettes with tumor cells. The cytolytic destruction of cancer cells by innate leukocytes is rapid and specific without apparent damage to normal cells. The mice are healthy, cancer-free and have a normal life span. These observations suggest a previously unrecognized mechanism of immune surveillance that may have potential for therapy or prevention of cancer.11-01-2012
20120276012Method of Treatment and Screening Method - A method for the prevention or treatment of a cardiovascular disease comprising increasing the intracellular creatine concentration in myocardial cells, in particular by up-regulating the creatine transporter. Also described are screening methods for identifying substances to be used in the prevention or treatment of a cardiovascular disease.11-01-2012
20120276011NANOPARTICULATE PROBE FOR IN VIVO MONITORING OF TISSUE OXYGENATION - A new class of micro- and nano-particulate paramagnetic spin probes useful for magnetic resonance imaging techniques, including electron paramagnetic resonance (EPR) and magnetic resonance imaging (MRI). The probes are lithium phthalocyanine derivative compounds. Also provided are suspensions and emulsions comprising lithium phthalocyanine derivative probes. Also provided are noninvasive methods for measuring noninvasive methods of measuring oxygen concentration, oxygen partial pressure, oxygen metabolism, and nitric oxide concentration in a specific tissue, organ, or cell in vivo or in vitro.11-01-2012
20100297021Variants of C-Type Natriuretic Peptide - The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).11-25-2010
20100297019PARTICLES FOR IMAGING - The invention encompasses particles comprising metal atoms, methods of making the particles, and methods for using the particles. In particular, the particles may be used to image biological tissues or to deliver a bioactive agent.11-25-2010
20100316575MODULATING BODY WEIGHT - This document provides methods and materials related to modulating body weight. For example, methods and materials related to treating obesity, reducing body weight, preventing body weight gain, increasing body weight, and identifying agents having the ability to treat obesity and reduce body weight are provided.12-16-2010
20100316574Oncofetal Antigen/Immature Laminin Receptor Peptides for the Sensitization of Dendritic Cells for Cancer Therapy - The present invention relates to methods of making peptides or a mixture of peptides that can be used to pulse dendritic cells against the oncofetal antigen/immature laminin receptor protein (OFA/iLRP). More specifically, dendritic cells can be derived from a range of different sources that can direct the immune system to attack specific antigens. Once sensitized, either ex vivo, in vivo or in vitro, the dendritic cells will aid an individual's own immune system to protect against or treat all types of OFA/iLRP-related cancer. The peptides may also be used for detection, diagnosis and monitoring, and treatment of a OFA/iLRP-related cancer.12-16-2010
20100316573Organic Compounds - A method to predict which patients will respond to a IAP inhibiting compound comprising: 12-16-2010
20130156703Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract - The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.06-20-2013
20130156704THERAPY FOR SUBARACHNOID HEMORRHAGE AND ISCHEMIA - The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery. Rupture is associated with higher mortality or increased debilitation if a subject survives. The trial provided evidence of significant benefit in subjects with and without aneurysm rupture before endovascular was surgery performed. Surprisingly, the subjects benefiting most from treatment as judged both by pathology and neurocognitive outcome were those in which the aneurysm had ruptured causing a subarachnoid hemorrhage. These data constitute evidence that a PSD-95 inhibitor is beneficial not only in ischemic and hemorrhagic stroke but in forms of hemorrhage in or affecting the CNS, particularly, subarachnoid hemorrhage.06-20-2013
20090304594Methods for Predicting Treatment Response Based On the Expression Profiles of Protein and Transcription Biomarkers - The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness to SAHA. The expression profile, or pattern, whether embodied in nucleic acid expression, protein expression, or other expression formats will find use in identifying and selecting patients afflicted with a particular HDAC mediated cancer who are likely to be non-responsive to SAHA-based therapy and thus candidates for other treatments.12-10-2009
20110286927ATF4 Inhibitors and Their Use for Neural Protection, Repair, Regeneration, and Plasticity - In one aspect, the invention relates to a method for identifying a drug candidate with activity as a neuroprotective agent. The method includes determining whether a compound reduces ATF4 activity; and identifying the compound that reduces ATF4 activity as a drug candidate.11-24-2011
20130121922METHODS FOR EVALUATING AND SELECTING DERMAL FILLER COMPOSITIONS - The present invention provides methods for selecting a cosmetically acceptable and effective dermal filler, with reduced chance of causing discoloration in skin of a patient.05-16-2013
20130121921Rodent Therapeutic Model And Methods - Rodent therapeutic models are provided containing at least human hepatocytes and at least one of human hematopoietic bone marrow cells and human cord blood. Such rodent therapeutic models can also be immunodeficient and/or contain human intestinal enzymes. These partially humanized rodent therapeutic models can have at least partially humanized bone marrow and a partially humanized liver. These rodent models include mice. The rodent models can be transplanted with one or more tumors, for example, xenotransplantation with a human tumor. Toxicological and efficacy trials of various therapies, for example, anti-cancer therapies, can be performed with these rodent therapeutic models. Oral administration of camptothecin can demonstrate increased toxicity in the humanized mice.05-16-2013
20130121923Treatment of Male Sexual Dysfunction - A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.05-16-2013
20120014879USE OF TUMOR NECROSIS FACTOR-alpha RECEPTOR p75 FOR TREATMENT OF ISCHEMIA-INDUCED NEOVASCULARIZATION - Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients.01-19-2012
20120027685DETERMINING THE CAPABILITY OF A TEST COMPOUND TO AFFECT SOLID TUMOR STEM CELLS - A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumor cells in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.02-02-2012
20120027684CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1 - The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.02-02-2012
20120027683DIABETES T CELL RECEPTORS - T cell receptors (TCRs) having the property of binding to a murine insulin-derived peptide, LYLVCGERG (SEQ ID NO:62), presented by the murine H-2K02-02-2012
20130195763METHODS AND COMPOSITIONS FOR IMPROVING SLEEP AND MEMORY - A method for determining whether a substance can increase the expression level of a fatty acid binding protein (FABP) in an animal. The method includes using a cell that includes an expression construct that comprises a FABP promoter operably linked to a polynucleotide sequence encoding a reporter molecule, wherein the cell is contacted with a candidate substance and then cultivating the cell under conditions conducive to expression of the reporter molecule. Increased expression of the construct in the presence of the candidate substance as compared to a control leads to improved sleep and long-term memory in the subject.08-01-2013
20130195762FAT CELLS AND METHODS OF USING THEREOF - Beige cells that contain a reporter gene are disclosed herein. Such cells can be used to identify therapeutic agents for treatment of obesity and its associated disorders, such as diabetes.08-01-2013
20120294804PHENYLETHANOLAMINE-BASED NMDA RECEPTOR ANTAGONISTS - Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment, e.g., of Formula (I):11-22-2012
20130202534PATHOLOGICAL ANIMAL MODEL SIMULTANEOUSLY DEVELOPING TESTICULAR PAIN OR DISCOMFORT BEHAVIORS AND URINARY FREQUENCY - A pathologic animal model characterized in that a pain or discomfort behavior and urinary frequency are induced by administering a stimulative substance into the testes of a small-sized mammal, and a screening method for a therapeutic agent for pelvic pain syndrome, particularly non-bacterial chronic prostatitis, which comprises administering a test substance to the pathologic animal model and measuring pain or discomfort behaviors and/or urinary frequency.08-08-2013
20130202533METHODS FOR MODULATING SKELETAL REMODELING AND PATTERNING BY MODULATING SHN2 ACTIVITY, SHN3 ACTIVITY, OR SHN2 AND SHN3 ACTIVITY IN COMBINATION - This invention is based, at least in part, on the discovery that Shn2 and Shn3 play an important role in skeletal remodeling and skeletal patterning. Accordingly, the present invention provides methods for identifying medulators of Shn2 activity and methods for modulating bone formation and mineralization and Shn2-associated disorders using agents that modulate Shn2 expression and/or activity, in addition to methods for modulating Shn2 and Shn3.08-08-2013

Patent applications in class Testing efficacy or toxicity of a compound or composition (e.g., drug, vaccine, etc.)